{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:09:12Z","timestamp":1794445752989,"version":"4.9.1"},"reference-count":671,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Program for Tumor Immunotherapy Technology Engineering Research Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is a chronic inflammatory illness with heterogeneous clinical manifestations covering multiple organs. Diversified types of medications have been shown effective for alleviating SLE syndromes, ranging from cytokines, antibodies, hormones, molecular inhibitors or antagonists, to cell transfusion. Drugs developed for treating other diseases may benefit SLE patients, and agents established as SLE therapeutics may be SLE-inductive. Complexities regarding SLE therapeutics render it essential and urgent to identify the mechanisms-of-action and pivotal signaling axis driving SLE pathogenesis, and to establish innovative SLE-targeting approaches with desirable therapeutic outcome and safety. After introducing the research history of SLE and its epidemiology, we categorized primary determinants driving SLE pathogenesis by their mechanisms; combed through current knowledge on SLE diagnosis and grouped them by disease onset, activity and comorbidity; introduced the genetic, epigenetic, hormonal and environmental factors predisposing SLE; and comprehensively categorized preventive strategies and available SLE therapeutics according to their functioning mechanisms. In summary, we proposed three mechanisms with determinant roles on SLE initiation and progression, i.e., attenuating the immune system, restoring the cytokine microenvironment homeostasis, and rescuing the impaired debris clearance machinery; and provided updated insights on current understandings of SLE regarding its pathogenesis, diagnosis, prevention and therapeutics, which may open an innovative avenue in the fields of SLE management.<\/jats:p>","DOI":"10.1038\/s41392-025-02168-0","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:09:11Z","timestamp":1742170151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":257,"title":["Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiaofeng","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"2168_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel, C. H. & Sammaritano, L. R. Systemic lupus erythematosus: A review. JAMA 331, 1480\u20131491 (2024).","journal-title":"JAMA"},{"key":"2168_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian, J., Zhang, D., Yao, X., Huang, Y. & Lu, Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann. Rheum. Dis. 82, 351\u2013356 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR3","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","volume":"42","author":"F Fatoye","year":"2022","unstructured":"Fatoye, F., Gebrye, T. & Mbada, C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatol. Int. 42, 2097\u20132107 (2022).","journal-title":"Rheumatol. Int."},{"key":"2168_CR4","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.berh.2018.09.004","volume":"32","author":"I Gergianaki","year":"2018","unstructured":"Gergianaki, I., Bortoluzzi, A. & Bertsias, G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best. Pract. Res. Clin. Rheumatol. 32, 188\u2013205 (2018).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"2168_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/art.38239","volume":"66","author":"SS Lim","year":"2014","unstructured":"Lim, S. S. et al. The incidence and prevalence of systemic lupus erythematosus, 2002\u20132004: The Georgia Lupus Registry. Arthritis Rheumatol. 66, 357\u2013368 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/art.38238","volume":"66","author":"EC Somers","year":"2014","unstructured":"Somers, E. C. et al. Population\u2010based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 66, 369\u2013378 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.02350314","volume":"10","author":"DJ Sexton","year":"2015","unstructured":"Sexton, D. J. et al. ESRD from lupus nephritis in the United States, 1995-2010. Clin. J. Am. Soc. Nephrol. 10, 251\u2013259 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2168_CR8","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul, A. et al. Systemic lupus erythematosus. Nat. Rev. Dis. Prim. 2, 16039 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2168_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/ard.2009.117200","volume":"69","author":"M Mosca","year":"2010","unstructured":"Mosca, M. et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann. Rheum. Dis. 69, 1269\u20131274 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2011.02.005","volume":"57","author":"L Mosca","year":"2011","unstructured":"Mosca, L. et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J. Am. Coll. Cardiol. 57, 1404\u20131423 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2168_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00296-019-04445-y","volume":"39","author":"SS Ahn","year":"2019","unstructured":"Ahn, S. S. et al. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol. Int. 39, 1937\u20131944 (2019).","journal-title":"Rheumatol. Int."},{"key":"2168_CR12","unstructured":"Norman, R. The history of lupus erythematosus and discoid lupus: From Hippocrates to the present. Lupus Open Access 1, 102 (2016)."},{"key":"2168_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"GJ Pons-Estel","year":"2010","unstructured":"Pons-Estel, G. J., Alarc\u00f3n, G. S., Scofield, L., Reinlib, L. & Cooper, G. S. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheu. 39, 257\u2013268 (2010).","journal-title":"Semin. Arthritis Rheu."},{"key":"2168_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/art.1780380415","volume":"38","author":"AE Johnson","year":"2005","unstructured":"Johnson, A. E., Gordon, C., Palmer, R. G. & Bacon, P. A. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Arthritis Rheum. 38, 551\u2013558 (2005).","journal-title":"Arthritis Rheum."},{"key":"2168_CR15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/rheumatology\/keu412","volume":"54","author":"C-S Yee","year":"2015","unstructured":"Yee, C.-S. et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology 54, 836\u2013843 (2015).","journal-title":"Rheumatology"},{"key":"2168_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/acr.22173","volume":"66","author":"M Yurkovich","year":"2014","unstructured":"Yurkovich, M., Vostretsova, K., Chen, W. J. & Avi\u00f1a-Zubieta, J. A. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res 66, 608\u2013616 (2014).","journal-title":"Arthritis Care Res"},{"key":"2168_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.berh.2009.04.005","volume":"23","author":"K Kumar","year":"2009","unstructured":"Kumar, K., Chambers, S. & Gordon, C. Challenges of ethnicity in SLE. Best. Pract. Res. Clin. Rheumatol. 23, 549\u2013561 (2009).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"2168_CR18","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/art.38006","volume":"65","author":"CC Mok","year":"2013","unstructured":"Mok, C. C., Kwok, R. C. L. & Yip, P. S. F. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 65, 2154\u20132160 (2013).","journal-title":"Arthritis Rheum."},{"key":"2168_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.rdc.2014.04.001","volume":"40","author":"LA Gonz\u00e1lez","year":"2014","unstructured":"Gonz\u00e1lez, L. A., Toloza, S. M. A. & Alarcon, G. S. Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 40, 433\u2013454 (2014).","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"2168_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/acr.21656","volume":"64","author":"C Flower","year":"2012","unstructured":"Flower, C. et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res 64, 1151\u20131158 (2012).","journal-title":"Arthritis Care Res"},{"key":"2168_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2188\/jea.JE20120204","volume":"24","author":"JH Ju","year":"2014","unstructured":"Ju, J. H. et al. Prevalence of systemic lupus erythematosus in South Korea: An administrative database study. J. Epidemiol. 24, 295\u2013303 (2014).","journal-title":"J. Epidemiol."},{"key":"2168_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00296-013-2915-9","volume":"34","author":"J-S Shim","year":"2013","unstructured":"Shim, J.-S., Sung, Y.-K., Joo, Y. B., Lee, H.-S. & Bae, S.-C. Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol. Int. 34, 909\u2013917 (2013).","journal-title":"Rheumatol. Int."},{"key":"2168_CR23","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00296-012-2643-6","volume":"33","author":"KW Yeh","year":"2013","unstructured":"Yeh, K. W., Yu, C. H., Chan, P. C., Horng, J. T. & Huang, J. L. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. Rheumatol. Int. 33, 1805\u20131811 (2013).","journal-title":"Rheumatol. Int."},{"key":"2168_CR24","doi-asserted-by":"crossref","unstructured":"Gustafsson, J. T. et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res. Ther. 14, R46 (2012).","DOI":"10.1186\/ar3759"},{"key":"2168_CR25","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526\u20131533 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR26","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou, H., Ling, G. S. & Cao, X. Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. J. Autoimmun. 132, 102861 (2022).","journal-title":"J. Autoimmun."},{"key":"2168_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clim.2016.09.002","volume":"185","author":"S Yung","year":"2017","unstructured":"Yung, S. & Chan, T. M. Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis. Clin. Immunol. 185, 40\u201350 (2017).","journal-title":"Clin. Immunol."},{"key":"2168_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nri3795","volume":"15","author":"SL Nutt","year":"2015","unstructured":"Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160\u2013171 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2168_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cellimm.2006.02.005","volume":"238","author":"D Rodr\u00edguez-Pinto","year":"2005","unstructured":"Rodr\u00edguez-Pinto, D. B cells as antigen presenting cells. Cell Immunol. 238, 67\u201375 (2005).","journal-title":"Cell Immunol."},{"key":"2168_CR30","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1084\/jem.20130699","volume":"210","author":"N Molnarfi","year":"2013","unstructured":"Molnarfi, N. et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 210, 2921\u20132937 (2013).","journal-title":"J. Exp. Med."},{"key":"2168_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"S Fillatreau","year":"2021","unstructured":"Fillatreau, S., Manfroi, B. & D\u00f6rner, T. Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat. Rev. Rheumatol. 17, 98\u2013108 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2177\/jsci.38.398","volume":"38","author":"S Iwata","year":"2015","unstructured":"Iwata, S. & Tanaka, Y. The importance of B cell-T cell interaction in autoimmune diseases. Nihon Rinsho Meneki Gakkai Kaishi 38, 398\u2013402 (2015).","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"2168_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-3532-1_1","volume":"1254","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Liu, J., Burrows, P. D. & Wang, J. Y. B Cell Development and Maturation. Adv. Exp. Med. Biol. 1254, 1\u201322 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2168_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear, H. M., Schoggins, J. W. & Diamond, M. S. Shared and distinct functions of type I and type III interferons. Immunity 50, 907\u2013923 (2019).","journal-title":"Immunity"},{"key":"2168_CR35","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","volume":"6","author":"L Ronnblom","year":"2019","unstructured":"Ronnblom, L. & Leonard, D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci. Med. 6, e000270 (2019).","journal-title":"Lupus Sci. Med."},{"key":"2168_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/imt-2016-0090","volume":"9","author":"W Greth","year":"2017","unstructured":"Greth, W., Robbie, G. J., Brohawn, P., Hultquist, M. & Yao, B. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus. Immunotherapy 9, 57\u201370 (2017).","journal-title":"Immunotherapy"},{"key":"2168_CR37","doi-asserted-by":"crossref","unstructured":"Ramaswamy, M., Tummala, R., Streicher, K., Nogueira da Costa, A. & Brohawn, P. Z. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int. J. Mol. Sci. 22, 11286 (2021).","DOI":"10.3390\/ijms222011286"},{"key":"2168_CR38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/art.30187","volume":"63","author":"CE Weckerle","year":"2011","unstructured":"Weckerle, C. E. et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 63, 1044\u20131053 (2011).","journal-title":"Arthritis Rheum."},{"key":"2168_CR39","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.immuni.2024.05.025","volume":"57","author":"H Xu","year":"2024","unstructured":"Xu, H. et al. Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity. Immunity 57, 1796\u20131811.e1798 (2024).","journal-title":"Immunity"},{"key":"2168_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","volume":"67","author":"M Postal","year":"2020","unstructured":"Postal, M. et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr. Opin. Immunol. 67, 87\u201394 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"2168_CR41","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41573-019-0043-2","volume":"18","author":"C Vanpouille-Box","year":"2019","unstructured":"Vanpouille-Box, C., Hoffmann, J. A. & Galluzzi, L. Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 18, 845\u2013867 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2168_CR42","doi-asserted-by":"publisher","first-page":"eadi9769","DOI":"10.1126\/sciimmunol.adi9769","volume":"9","author":"C Wolf","year":"2024","unstructured":"Wolf, C. et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci. Immunol. 9, eadi9769 (2024).","journal-title":"Sci. Immunol."},{"key":"2168_CR43","doi-asserted-by":"publisher","first-page":"103155","DOI":"10.1016\/j.autrev.2022.103155","volume":"21","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: Biologic function, mechanisms and clinical prospection. Autoimmun. Rev. 21, 103155 (2022).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR44","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nri.2016.78","volume":"16","author":"M Schlee","year":"2016","unstructured":"Schlee, M. & Hartmann, G. Discriminating self from non-self in nucleic acid sensing. Nat. Rev. Immunol. 16, 566\u2013580 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2168_CR45","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-immunol-051116-052331","volume":"35","author":"JT Crowl","year":"2017","unstructured":"Crowl, J. T., Gray, E. E., Pestal, K., Volkman, H. E. & Stetson, D. B. Intracellular nucleic acid detection in autoimmunity. Annu. Rev. Immunol. 35, 313\u2013336 (2017).","journal-title":"Annu. Rev. Immunol."},{"key":"2168_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64865-w","volume":"10","author":"S Skopelja-Gardner","year":"2020","unstructured":"Skopelja-Gardner, S. et al. The early local and systemic Type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci. Rep. 10, 7908 (2020).","journal-title":"Sci. Rep."},{"key":"2168_CR47","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.it.2017.04.002","volume":"38","author":"S Halle","year":"2017","unstructured":"Halle, S., Halle, O. & F\u00f6rster, R. Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo. Trends Immunol. 38, 432\u2013443 (2017).","journal-title":"Trends Immunol."},{"key":"2168_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","volume":"177","author":"JG Cyster","year":"2019","unstructured":"Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524\u2013540 (2019).","journal-title":"Cell"},{"key":"2168_CR49","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","volume":"187","author":"H Chi","year":"2024","unstructured":"Chi, H., Pepper, M. & Thomas, P. G. Principles and therapeutic applications of adaptive immunity. Cell 187, 2052\u20132078 (2024).","journal-title":"Cell"},{"key":"2168_CR50","doi-asserted-by":"crossref","unstructured":"Zhu, J., Yamane, H. & Paul, W. E. Differentiation of effect or CD4 T cell populations (*). Annu. Rev. Immunol. 28, 445\u2013489 (2010).","DOI":"10.1146\/annurev-immunol-030409-101212"},{"key":"2168_CR51","doi-asserted-by":"publisher","first-page":"103213","DOI":"10.1016\/j.autrev.2022.103213","volume":"22","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus. Autoimmun. Rev. 22, 103213 (2023).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR52","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s10753-011-9419-0","volume":"35","author":"H Fujie","year":"2012","unstructured":"Fujie, H. et al. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. Inflammation 35, 1119\u20131131 (2012).","journal-title":"Inflammation"},{"key":"2168_CR53","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1172\/JCI81227","volume":"125","author":"S B\u00e9zie","year":"2015","unstructured":"B\u00e9zie, S. et al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J. Clin. Invest. 125, 3952\u20133964 (2015).","journal-title":"J. Clin. Invest."},{"key":"2168_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan, Y. et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J. Hematol. Oncol. 15, 104 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2168_CR55","doi-asserted-by":"publisher","first-page":"9943743","DOI":"10.1155\/2021\/9943743","volume":"2021","author":"X Xia","year":"2021","unstructured":"Xia, X., Yang, J. & Wang, S. Follicular regulatory T cells in systemic lupus erythematosus. J. Immunol. Res 2021, 9943743 (2021).","journal-title":"J. Immunol. Res"},{"key":"2168_CR56","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/schbul\/sbae011","volume":"50","author":"CMJ Wannan","year":"2024","unstructured":"Wannan, C. M. J. et al. Accelerating Medicines Partnership(R) Schizophrenia (AMP(R) SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophr. Bull. 50, 496\u2013512 (2024).","journal-title":"Schizophr. Bull."},{"key":"2168_CR57","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-024-07627-2","volume":"631","author":"C Law","year":"2024","unstructured":"Law, C. et al. Interferon subverts an AHR-JUN axis to promote CXCL13(\u2009+\u2009) T cells in lupus. Nature 631, 857\u2013866 (2024).","journal-title":"Nature"},{"key":"2168_CR58","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/annrheumdis-2021-221985","volume":"81","author":"Z Zhao","year":"2022","unstructured":"Zhao, Z. et al. Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity. Ann. Rheum. Dis. 81, 1006\u20131012 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR59","doi-asserted-by":"publisher","first-page":"102976","DOI":"10.1016\/j.jaut.2022.102976","volume":"134","author":"X Wei","year":"2023","unstructured":"Wei, X. & Niu, X. T follicular helper cells in autoimmune diseases. J. Autoimmun. 134, 102976 (2023).","journal-title":"J. Autoimmun."},{"key":"2168_CR60","doi-asserted-by":"publisher","first-page":"107575","DOI":"10.1016\/j.celrep.2020.107575","volume":"31","author":"E Shen","year":"2020","unstructured":"Shen, E. et al. Control of germinal center localization and lineage stability of follicular regulatory T cells by the Blimp1 transcription factor. Cell Rep. 31, 107575 (2020).","journal-title":"Cell Rep."},{"key":"2168_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.kint.2022.02.035","volume":"102","author":"AM Newman-Rivera","year":"2022","unstructured":"Newman-Rivera, A. M., Kurzhagen, J. T. & Rabb, H. TCRalphabeta+ CD4-\/CD8- \u201cdouble negative\u201d T cells in health and disease-implications for the kidney. Kidney Int 102, 25\u201337 (2022).","journal-title":"Kidney Int"},{"key":"2168_CR62","doi-asserted-by":"publisher","first-page":"102653","DOI":"10.1016\/j.jaut.2021.102653","volume":"121","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Transcriptome landscape of double negative T cells by single-cell RNA sequencing. J. Autoimmun. 121, 102653 (2021).","journal-title":"J. Autoimmun."},{"key":"2168_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16636-4","volume":"11","author":"H Li","year":"2020","unstructured":"Li, H. et al. Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nat. Commun. 11, 2859 (2020).","journal-title":"Nat. Commun."},{"key":"2168_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/BOR.0000000000000778","volume":"33","author":"H Li","year":"2021","unstructured":"Li, H. & Tsokos, G. C. Double-negative T cells in autoimmune diseases. Curr. Opin. Rheumatol. 33, 163\u2013172 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2168_CR65","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.autrev.2018.02.001","volume":"17","author":"D Brandt","year":"2018","unstructured":"Brandt, D. & Hedrich, C. M. TCR\u03b1\u03b2(\u2009+\u2009)CD3(\u2009+\u2009)CD4(-)CD8(-) (double negative) T cells in autoimmunity. Autoimmun. Rev. 17, 422\u2013430 (2018).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41392-023-01709-9","volume":"9","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis. Signal Transduct. Target Ther. 9, 18 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2168_CR67","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/art.42840","volume":"76","author":"W Li","year":"2024","unstructured":"Li, W. et al. Phosphatidic acid promoting the generation of interleukin-17A producing double-negative T cells by enhancing mTORC1 signaling in lupus. Arthritis Rheumatol. 76, 1096\u20131108 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1568010043483944","volume":"3","author":"ML Salem","year":"2004","unstructured":"Salem, M. L. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1\/TH2 cytokine production. Curr. Drug. Targets Inflamm. Allergy 3, 97\u2013104 (2004).","journal-title":"Curr. Drug. Targets Inflamm. Allergy"},{"key":"2168_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong, C. Cytokine regulation and function in T cells. Annu. Rev. Immunol. 39, 51\u201376 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"2168_CR70","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fimmu.2019.00391","volume":"10","author":"L Alvarez-Rodriguez","year":"2019","unstructured":"Alvarez-Rodriguez, L. et al. Altered Th17\/Treg ratio in peripheral blood of systemic lupus erythematosus but not primary antiphospholipid syndrome. Front. Immunol. 10, 391 (2019).","journal-title":"Front. Immunol."},{"key":"2168_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","volume":"72","author":"RM Talaat","year":"2015","unstructured":"Talaat, R. M., Mohamed, S. F., Bassyouni, I. H. & Raouf, A. A. Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 72, 146\u2013153 (2015).","journal-title":"Cytokine"},{"key":"2168_CR72","doi-asserted-by":"publisher","first-page":"e13012","DOI":"10.1111\/eci.13012","volume":"48","author":"M Chen","year":"2018","unstructured":"Chen, M., Chen, X. & Wan, Q. Altered frequency of Th17 and Treg cells in new-onset systemic lupus erythematosus patients. Eur. J. Clin. Invest. 48, e13012 (2018).","journal-title":"Eur. J. Clin. Invest."},{"key":"2168_CR73","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916934.2015.1037441","volume":"48","author":"D Li","year":"2015","unstructured":"Li, D. et al. Interleukin-17 in systemic lupus erythematosus: A comprehensive review. Autoimmunity 48, 353\u2013361 (2015).","journal-title":"Autoimmunity"},{"key":"2168_CR74","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0961203319828530","volume":"28","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. Regulatory T-cell levels in systemic lupus erythematosus patients: a meta-analysis. Lupus 28, 445\u2013454 (2019).","journal-title":"Lupus"},{"key":"2168_CR75","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/eji.201344280","volume":"45","author":"K Ohl","year":"2015","unstructured":"Ohl, K. & Tenbrock, K. Regulatory T cells in systemic lupus erythematosus. Eur. J. Immunol. 45, 344\u2013355 (2015).","journal-title":"Eur. J. Immunol."},{"key":"2168_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11926-018-0714-8","volume":"20","author":"A La Cava","year":"2018","unstructured":"La Cava, A. Tregs in SLE: an update. Curr. Rheumatol. Rep. 20, 6 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"2168_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1172\/JCI76012","volume":"125","author":"VA Gerriets","year":"2015","unstructured":"Gerriets, V. A. et al. Metabolic programming and PDHK1 control CD4\u2009+\u2009T cell subsets and inflammation. J. Clin. Invest. 125, 194\u2013207 (2015).","journal-title":"J. Clin. Invest."},{"key":"2168_CR78","doi-asserted-by":"publisher","first-page":"9288","DOI":"10.1073\/pnas.1805717115","volume":"115","author":"M Kono","year":"2018","unstructured":"Kono, M. et al. Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation. Proc. Natl Acad. Sci. Usa. 115, 9288\u20139293 (2018).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"2168_CR79","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.4049\/jimmunol.1601765","volume":"200","author":"KW Kalim","year":"2018","unstructured":"Kalim, K. W. et al. Reciprocal regulation of glycolysis-driven Th17 pathogenicity and regulatory T cell stability by Cdc42. J. Immunol. 200, 2313\u20132326 (2018).","journal-title":"J. Immunol."},{"key":"2168_CR80","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fimmu.2019.00115","volume":"10","author":"D Cluxton","year":"2019","unstructured":"Cluxton, D., Petrasca, A., Moran, B. & Fletcher, J. M. Differential regulation of human treg and Th17 cells by fatty acid synthesis and glycolysis. Front. Immunol. 10, 115 (2019).","journal-title":"Front. Immunol."},{"key":"2168_CR81","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/eji.201445422","volume":"46","author":"CY Sasaki","year":"2016","unstructured":"Sasaki, C. Y. et al. p((7)(0)S(6)K(1)) in the TORC1 pathway is essential for the differentiation of Th17 Cells, but not Th1, Th2, or Treg cells in mice. Eur. J. Immunol. 46, 212\u2013222 (2016).","journal-title":"Eur. J. Immunol."},{"key":"2168_CR82","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1096\/fj.201600522R","volume":"30","author":"GA Gualdoni","year":"2016","unstructured":"Gualdoni, G. A. et al. The AMP analog AICAR modulates the Treg\/Th17 axis through enhancement of fatty acid oxidation. FASEB J. 30, 3800\u20133809 (2016).","journal-title":"FASEB J."},{"key":"2168_CR83","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.jaut.2022.102979","volume":"137","author":"SL Coss","year":"2023","unstructured":"Coss, S. L. et al. The complement system and human autoimmune diseases. J. Autoimmun. 137, 102979 (2023).","journal-title":"J. Autoimmun."},{"key":"2168_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13046-019-1514-3","volume":"39","author":"K Yuan","year":"2020","unstructured":"Yuan, K. et al. Complement C3 overexpression activates JAK2\/STAT3 pathway and correlates with gastric cancer progression. J. Exp. Clin. Cancer Res. 39, 9 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2168_CR85","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri, M. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550\u20132558 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR86","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271\u20131277 (1982).","journal-title":"Arthritis Rheum."},{"key":"2168_CR87","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).","journal-title":"Arthritis Rheum."},{"key":"2168_CR88","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer, M. et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1151\u20131159 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/annrheumdis-2018-214685","volume":"78","author":"SK Tedeschi","year":"2019","unstructured":"Tedeschi, S. K. et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78, 634\u2013640 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR90","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3899\/jrheum.130704","volume":"41","author":"MB Urowitz","year":"2014","unstructured":"Urowitz, M. B. et al. American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J. Rheumatol. 41, 875\u2013880 (2014).","journal-title":"J. Rheumatol."},{"key":"2168_CR91","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u2013291 (2002).","journal-title":"J. Rheumatol."},{"key":"2168_CR92","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677\u20132686 (2012).","journal-title":"Arthritis Rheum."},{"key":"2168_CR93","first-page":"1265","volume":"22","author":"M Abu-Shakra","year":"1995","unstructured":"Abu-Shakra, M., Urowitz, M. B., Gladman, D. D. & Gough, J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables Mortal. J. Rheumatol. 22, 1265\u20131270 (1995).","journal-title":"Predictor variables Mortal. J. Rheumatol."},{"key":"2168_CR94","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/anr.1780320909","volume":"32","author":"MH Liang","year":"1989","unstructured":"Liang, M. H., Socher, S. A., Larson, M. G. & Schur, P. H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 32, 1107\u20131118 (1989).","journal-title":"Arthritis Rheum."},{"key":"2168_CR95","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D. & Chang, C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35, 630\u2013640 (1992).","journal-title":"Arthritis Rheum."},{"key":"2168_CR96","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203310385163","volume":"20","author":"Z Touma","year":"2011","unstructured":"Touma, Z., Urowitz, M. B., Ibanez, D. & Gladman, D. D. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 20, 67\u201370 (2011).","journal-title":"Lupus"},{"key":"2168_CR97","first-page":"336","volume":"34","author":"D Ibanez","year":"2007","unstructured":"Ibanez, D., Gladman, D. & Urowitz, M. Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J. Rheumatol. 34, 336\u2013340 (2007).","journal-title":"J. Rheumatol."},{"key":"2168_CR98","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","volume":"78","author":"D Jesus","year":"2019","unstructured":"Jesus, D. et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann. Rheum. Dis. 78, 365\u2013371 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR99","first-page":"927","volume":"69","author":"DP Symmons","year":"1988","unstructured":"Symmons, D. P. et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 69, 927\u2013937 (1988).","journal-title":"Q. J. Med."},{"key":"2168_CR100","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","volume":"44","author":"DA Isenberg","year":"2005","unstructured":"Isenberg, D. A. et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus. Rheumatol. (Oxf.) 44, 902\u2013906 (2005).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR101","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/rheumatology\/keq026","volume":"49","author":"CS Yee","year":"2010","unstructured":"Yee, C. S. et al. Numerical scoring for the BILAG-2004 index. Rheumatol. (Oxf.) 49, 1665\u20131669 (2010).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR102","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace, D. J. et al. Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. 73, 183\u2013190 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR103","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR104","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/acr2.11414","volume":"4","author":"MF Loncharich","year":"2022","unstructured":"Loncharich, M. F. & Anderson, C. W. Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval. ACR Open Rheumatol. 4, 486\u2013491 (2022).","journal-title":"ACR Open Rheumatol."},{"key":"2168_CR105","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/art.41778","volume":"73","author":"R Furie","year":"2021","unstructured":"Furie, R. et al. What does it mean to be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post hoc analysis of two phase III trials. Arthritis Rheumatol. 73, 2059\u20132068 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR106","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse, M. E. et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 69, 362\u2013375 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR107","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","volume":"76","author":"DJ Wallace","year":"2017","unstructured":"Wallace, D. J. et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann. Rheum. Dis. 76, 534\u2013542 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR108","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","volume":"79","author":"FA Houssiau","year":"2020","unstructured":"Houssiau, F. A. et al. IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann. Rheum. Dis. 79, 347\u2013355 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR109","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242\u2013252 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR110","doi-asserted-by":"crossref","unstructured":"Merrill, J. T. et al. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: a phase 2 randomized controlled trial. Arthritis Rheumatol. 76, 1518\u20131529 (2024).","DOI":"10.1002\/art.42926"},{"key":"2168_CR111","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3899\/jrheum.100724","volume":"38","author":"Z Touma","year":"2011","unstructured":"Touma, Z., Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J. Rheumatol. 38, 275\u2013284 (2011).","journal-title":"J. Rheumatol."},{"key":"2168_CR112","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie, R. A. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61, 1143\u20131151 (2009).","journal-title":"Arthritis Rheum."},{"key":"2168_CR113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman, D. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363\u2013369 (1996).","journal-title":"Arthritis Rheum."},{"key":"2168_CR114","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/art.1780400506","volume":"40","author":"DD Gladman","year":"1997","unstructured":"Gladman, D. D. et al. The reliability of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 40, 809\u2013813 (1997).","journal-title":"Arthritis Rheum."},{"key":"2168_CR115","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1191\/096120301670679959","volume":"10","author":"P Rahman","year":"2001","unstructured":"Rahman, P., Gladman, D. D., Urowitz, M. B., Hallett, D. & Tam, L. S. Early damage as measured by the SLICC\/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10, 93\u201396 (2001).","journal-title":"Lupus"},{"key":"2168_CR116","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","volume":"74","author":"IN Bruce","year":"2015","unstructured":"Bruce, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 74, 1706\u20131713 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR117","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14712598.2019.1561856","volume":"19","author":"I Parodis","year":"2019","unstructured":"Parodis, I. et al. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. Expert Opin. Biol. Ther. 19, 157\u2013168 (2019).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2168_CR118","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3899\/jrheum.100007","volume":"37","author":"AJ Steiman","year":"2010","unstructured":"Steiman, A. J., Gladman, D. D., Ibanez, D. & Urowitz, M. B. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J. Rheumatol. 37, 1822\u20131827 (2010).","journal-title":"J. Rheumatol."},{"key":"2168_CR119","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn, K. et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann. Rheum. Dis. 75, 1615\u20131621 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR120","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/acr.22591","volume":"67","author":"DJ Tunnicliffe","year":"2015","unstructured":"Tunnicliffe, D. J., Singh-Grewal, D., Kim, S., Craig, J. C. & Tong, A. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res. (Hoboken) 67, 1440\u20131452 (2015).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR121","first-page":"70","volume":"34","author":"MB Urowitz","year":"2007","unstructured":"Urowitz, M. B., Ibanez, D. & Gladman, D. D. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J. Rheumatol. 34, 70\u201375 (2007).","journal-title":"J. Rheumatol."},{"key":"2168_CR122","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.20568","volume":"64","author":"IE Bultink","year":"2012","unstructured":"Bultink, I. E. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 64, 2\u20138 (2012).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR123","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrneurol.2014.148","volume":"10","author":"H Jeltsch-David","year":"2014","unstructured":"Jeltsch-David, H. & Muller, S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat. Rev. Neurol. 10, 579\u2013596 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"2168_CR124","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3899\/jrheum.100575","volume":"38","author":"D Ibanez","year":"2011","unstructured":"Ibanez, D., Gladman, D. D., Touma, Z., Nikpour, M. & Urowitz, M. B. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. J. Rheumatol. 38, 60\u201363 (2011).","journal-title":"J. Rheumatol."},{"key":"2168_CR125","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1002\/art.41414","volume":"72","author":"J Cui","year":"2020","unstructured":"Cui, J. et al. Interactions between genome-wide genetic factors and smoking influencing risk of systemic lupus erythematosus. Arthritis Rheumatol. 72, 1863\u20131871 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR126","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/annrheumdis-2016-209157","volume":"76","author":"KA Young","year":"2017","unstructured":"Young, K. A. et al. Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann. Rheum. Dis. 76, 153\u2013158 (2017).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 3","key":"2168_CR127","doi-asserted-by":"publisher","first-page":"S279","DOI":"10.1186\/ar586","volume":"4","author":"MJ Walport","year":"2002","unstructured":"Walport, M. J. Complement and systemic lupus erythematosus. Arthritis Res. 4(Suppl 3), S279\u2013S293 (2002).","journal-title":"Arthritis Res."},{"key":"2168_CR128","doi-asserted-by":"crossref","unstructured":"Kwon, Y. C., Chun, S., Kim, K. & Mak, A. Update on the genetics of systemic lupus erythematosus: genome-wide association studies and beyond. Cells 8, 1180 (2019).","DOI":"10.3390\/cells8101180"},{"key":"2168_CR129","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/gene.2009.39","volume":"10","author":"KL Moser","year":"2009","unstructured":"Moser, K. L., Kelly, J. A., Lessard, C. J. & Harley, J. B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 10, 373\u2013379 (2009).","journal-title":"Genes Immun."},{"key":"2168_CR130","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1001\/jamainternmed.2015.3528","volume":"175","author":"CF Kuo","year":"2015","unstructured":"Kuo, C. F. et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern. Med. 175, 1518\u20131526 (2015).","journal-title":"JAMA Intern. Med."},{"key":"2168_CR131","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ajhg.2020.09.007","volume":"107","author":"KA Owen","year":"2020","unstructured":"Owen, K. A. et al. Analysis of trans-ancestral SLE risk loci identifies unique biologic networks and drug targets in African and European ancestries. Am. J. Hum. Genet. 107, 864\u2013881 (2020).","journal-title":"Am. J. Hum. Genet."},{"key":"2168_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16021","volume":"8","author":"CD Langefeld","year":"2017","unstructured":"Langefeld, C. D. et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat. Commun. 8, 16021 (2017).","journal-title":"Nat. Commun."},{"key":"2168_CR133","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1681\/ASN.2013050446","volume":"25","author":"SA Chung","year":"2014","unstructured":"Chung, S. A. et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J. Am. Soc. Nephrol. 25, 2859\u20132870 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2168_CR134","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ng.3496","volume":"48","author":"C Sun","year":"2016","unstructured":"Sun, C. et al. High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nat. Genet. 48, 323\u2013330 (2016).","journal-title":"Nat. Genet."},{"key":"2168_CR135","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/annrheumdis-2019-216227","volume":"79","author":"S Reid","year":"2020","unstructured":"Reid, S. et al. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. Ann. Rheum. Dis. 79, 363\u2013369 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR136","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2011-200385","volume":"71","author":"T Hughes","year":"2012","unstructured":"Hughes, T. et al. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann. Rheum. Dis. 71, 694\u2013699 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR137","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.rdc.2014.04.002","volume":"40","author":"JA James","year":"2014","unstructured":"James, J. A. Clinical perspectives on lupus genetics: Advances and opportunities. Rheum. Dis. Clin. N. Am. 40, 413\u2013432 (2014). vii.","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"2168_CR138","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/gene.2010.73","volume":"12","author":"B Namjou","year":"2011","unstructured":"Namjou, B. et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12, 270\u2013279 (2011).","journal-title":"Genes Immun."},{"key":"2168_CR139","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/08916930701510673","volume":"40","author":"L Truedsson","year":"2007","unstructured":"Truedsson, L., Bengtsson, A. A. & Sturfelt, G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40, 560\u2013566 (2007).","journal-title":"Autoimmunity"},{"key":"2168_CR140","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/art.23613","volume":"58","author":"TB Niewold","year":"2008","unstructured":"Niewold, T. B. et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58, 2481\u20132487 (2008).","journal-title":"Arthritis Rheum."},{"key":"2168_CR141","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/art.21031","volume":"52","author":"KA Kirou","year":"2005","unstructured":"Kirou, K. A. et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491\u20131503 (2005).","journal-title":"Arthritis Rheum."},{"key":"2168_CR142","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/01.bor.0000135453.70424.1b","volume":"16","author":"MK Crow","year":"2004","unstructured":"Crow, M. K. & Kirou, K. A. Interferon-alpha in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16, 541\u2013547 (2004).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2168_CR143","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/hmg\/ddm359","volume":"17","author":"S Sigurdsson","year":"2008","unstructured":"Sigurdsson, S. et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5\u2009bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum. Mol. Genet. 17, 872\u2013881 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"2168_CR144","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/ard.2008.097642","volume":"68","author":"AK Abelson","year":"2009","unstructured":"Abelson, A. K. et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann. Rheum. Dis. 68, 1746\u20131753 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR145","doi-asserted-by":"publisher","first-page":"e1000084","DOI":"10.1371\/journal.pgen.1000084","volume":"4","author":"KE Taylor","year":"2008","unstructured":"Taylor, K. E. et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 4, e1000084 (2008).","journal-title":"PLoS Genet"},{"key":"2168_CR146","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/ng.472","volume":"41","author":"JW Han","year":"2009","unstructured":"Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234\u20131237 (2009).","journal-title":"Nat. Genet."},{"key":"2168_CR147","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ajhg.2012.02.023","volume":"90","author":"CJ Lessard","year":"2012","unstructured":"Lessard, C. J. et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 90, 648\u2013660 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"2168_CR148","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.1073\/pnas.0901181106","volume":"106","author":"CO Jacob","year":"2009","unstructured":"Jacob, C. O. et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 106, 6256\u20136261 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR149","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/gene.2009.15","volume":"10","author":"SN Kariuki","year":"2009","unstructured":"Kariuki, S. N. et al. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 10, 487\u2013494 (2009).","journal-title":"Genes Immun."},{"key":"2168_CR150","doi-asserted-by":"publisher","first-page":"e1002128","DOI":"10.1371\/journal.pgen.1002128","volume":"7","author":"X Luo","year":"2011","unstructured":"Luo, X. et al. A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 7, e1002128 (2011).","journal-title":"PLoS Genet"},{"key":"2168_CR151","doi-asserted-by":"publisher","first-page":"584374","DOI":"10.1155\/2012\/584374","volume":"2012","author":"M Relle","year":"2012","unstructured":"Relle, M. & Schwarting, A. Role of MHC-linked susceptibility genes in the pathogenesis of human and murine lupus. Clin. Dev. Immunol. 2012, 584374 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"2168_CR152","doi-asserted-by":"publisher","first-page":"e1008092","DOI":"10.1371\/journal.pgen.1008092","volume":"15","author":"JE Molineros","year":"2019","unstructured":"Molineros, J. E. et al. Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. PLoS Genet 15, e1008092 (2019).","journal-title":"PLoS Genet"},{"key":"2168_CR153","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ng.79","volume":"40","author":"SV Kozyrev","year":"2008","unstructured":"Kozyrev, S. V. et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat. Genet. 40, 211\u2013216 (2008).","journal-title":"Nat. Genet."},{"key":"2168_CR154","doi-asserted-by":"publisher","first-page":"e1001311","DOI":"10.1371\/journal.pgen.1001311","volume":"7","author":"KE Taylor","year":"2011","unstructured":"Taylor, K. E. et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet 7, e1001311 (2011).","journal-title":"PLoS Genet"},{"key":"2168_CR155","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/ng.200","volume":"40","author":"RR Graham","year":"2008","unstructured":"Graham, R. R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40, 1059\u20131061 (2008).","journal-title":"Nat. Genet."},{"key":"2168_CR156","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1086\/423790","volume":"75","author":"C Kyogoku","year":"2004","unstructured":"Kyogoku, C. et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75, 504\u2013507 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"2168_CR157","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/08916930701510848","volume":"40","author":"SA Chung","year":"2007","unstructured":"Chung, S. A. & Criswell, L. A. PTPN22: its role in SLE and autoimmunity. Autoimmunity 40, 582\u2013590 (2007).","journal-title":"Autoimmunity"},{"key":"2168_CR158","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/gene.2009.19","volume":"10","author":"R Lu","year":"2009","unstructured":"Lu, R. et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 10, 397\u2013403 (2009).","journal-title":"Genes Immun."},{"key":"2168_CR159","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2011-200987","volume":"71","author":"AM Delgado-Vega","year":"2012","unstructured":"Delgado-Vega, A. M. et al. Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein. Ann. Rheum. Dis. 71, 1219\u20131226 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR160","doi-asserted-by":"publisher","first-page":"e1002455","DOI":"10.1371\/journal.pgen.1002455","volume":"8","author":"Y Okada","year":"2012","unstructured":"Okada, Y. et al. A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet 8, e1002455 (2012).","journal-title":"PLoS Genet"},{"key":"2168_CR161","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1136\/ard.2010.146530","volume":"70","author":"VM Vazgiourakis","year":"2011","unstructured":"Vazgiourakis, V. M. et al. A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. Ann. Rheum. Dis. 70, 2184\u20132190 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR162","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.2439","volume":"44","author":"N Manjarrez-Orduno","year":"2012","unstructured":"Manjarrez-Orduno, N. et al. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat. Genet. 44, 1227\u20131230 (2012).","journal-title":"Nat. Genet."},{"key":"2168_CR163","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1073\/pnas.1113251108","volume":"109","author":"CO Jacob","year":"2012","unstructured":"Jacob, C. O. et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc. Natl. Acad. Sci. USA 109, E59\u2013E67 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR164","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/art.30188","volume":"63","author":"K Hikami","year":"2011","unstructured":"Hikami, K. et al. Association of a functional polymorphism in the 3\u2019-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum. 63, 755\u2013763 (2011).","journal-title":"Arthritis Rheum."},{"key":"2168_CR165","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","volume":"10","author":"JM Thurman","year":"2019","unstructured":"Thurman, J. M. & Yapa, R. Complement therapeutics in autoimmune disease. Front. Immunol. 10, 672 (2019).","journal-title":"Front. Immunol."},{"key":"2168_CR166","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1600-065X.1999.tb01398.x","volume":"167","author":"P Price","year":"1999","unstructured":"Price, P. et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol. Rev. 167, 257\u2013274 (1999).","journal-title":"Immunol. Rev."},{"key":"2168_CR167","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.ejhg.5201827","volume":"15","author":"RR Graham","year":"2007","unstructured":"Graham, R. R. et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 15, 823\u2013830 (2007).","journal-title":"Eur. J. Hum. Genet."},{"key":"2168_CR168","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ng0598-56","volume":"19","author":"M Botto","year":"1998","unstructured":"Botto, M. et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19, 56\u201359 (1998).","journal-title":"Nat. Genet."},{"key":"2168_CR169","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.4049\/jimmunol.1001731","volume":"185","author":"DM Santer","year":"2010","unstructured":"Santer, D. M. et al. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J. Immunol. 185, 4738\u20134749 (2010).","journal-title":"J. Immunol."},{"key":"2168_CR170","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aao4555","volume":"360","author":"GS Ling","year":"2018","unstructured":"Ling, G. S. et al. C1q restrains autoimmunity and viral infection by regulating CD8(\u2009+\u2009) T cell metabolism. Science 360, 558\u2013563 (2018).","journal-title":"Science"},{"key":"2168_CR171","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/0961203311430702","volume":"21","author":"CW Cao","year":"2012","unstructured":"Cao, C. W. et al. Association study of C1qA polymorphisms with systemic lupus erythematosus in a Han population. Lupus 21, 502\u2013507 (2012).","journal-title":"Lupus"},{"key":"2168_CR172","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/art.1780350515","volume":"35","author":"Y Suzuki","year":"1992","unstructured":"Suzuki, Y., Ogura, Y., Otsubo, O., Akagi, K. & Fujita, T. Selective deficiency of C1s associated with a systemic lupus erythematosus-like syndrome. Report of a case. Arthritis Rheum. 35, 576\u2013579 (1992).","journal-title":"Arthritis Rheum."},{"key":"2168_CR173","first-page":"455","volume":"87","author":"P Bowness","year":"1994","unstructured":"Bowness, P. et al. Hereditary C1q deficiency and systemic lupus erythematosus. QJM 87, 455\u2013464 (1994).","journal-title":"QJM"},{"key":"2168_CR174","doi-asserted-by":"publisher","first-page":"e14742","DOI":"10.1371\/journal.pone.0014742","volume":"6","author":"M El Baroudi","year":"2011","unstructured":"El Baroudi, M., Cora, D., Bosia, C., Osella, M. & Caselle, M. A curated database of miRNA mediated feed-forward loops involving MYC as master regulator. PLoS One 6, e14742 (2011).","journal-title":"PLoS One"},{"key":"2168_CR175","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/art.24436","volume":"60","author":"Y Tang","year":"2009","unstructured":"Tang, Y. et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60, 1065\u20131075 (2009).","journal-title":"Arthritis Rheum."},{"key":"2168_CR176","doi-asserted-by":"publisher","first-page":"e10344","DOI":"10.1371\/journal.pone.0010344","volume":"5","author":"JL Te","year":"2010","unstructured":"Te, J. L. et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 5, e10344 (2010).","journal-title":"PLoS One"},{"key":"2168_CR177","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00296-008-0758-6","volume":"29","author":"Y Dai","year":"2009","unstructured":"Dai, Y. et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol. Int. 29, 749\u2013754 (2009).","journal-title":"Rheumatol. Int."},{"key":"2168_CR178","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/ard.2010.139857","volume":"70","author":"E Stagakis","year":"2011","unstructured":"Stagakis, E. et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: MiR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann. Rheum. Dis. 70, 1496\u20131506 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR179","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/art.30196","volume":"63","author":"S Zhao","year":"2011","unstructured":"Zhao, S. et al. MicroRNA-126 regulates DNA methylation in CD4\u2009+\u2009T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 63, 1376\u20131386 (2011).","journal-title":"Arthritis Rheum."},{"key":"2168_CR180","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1073\/pnas.0610731104","volume":"104","author":"RM O\u2019Connell","year":"2007","unstructured":"O\u2019Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G. & Baltimore, D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. USA 104, 1604\u20131609 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR181","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.4049\/jimmunol.179.8.5082","volume":"179","author":"E Tili","year":"2007","unstructured":"Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide\/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179, 5082\u20135089 (2007).","journal-title":"J. Immunol."},{"key":"2168_CR182","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.4049\/jimmunol.1000491","volume":"185","author":"P Wang","year":"2010","unstructured":"Wang, P. et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J. Immunol. 185, 6226\u20136233 (2010).","journal-title":"J. Immunol."},{"key":"2168_CR183","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1073\/pnas.0902636106","volume":"106","author":"RM O\u2019Connell","year":"2009","unstructured":"O\u2019Connell, R. M., Chaudhuri, A. A., Rao, D. S. & Baltimore, D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. USA 106, 7113\u20137118 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR184","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.febslet.2010.02.063","volume":"584","author":"B Tang","year":"2010","unstructured":"Tang, B. et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett. 584, 1481\u20131486 (2010).","journal-title":"FEBS Lett."},{"key":"2168_CR185","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1073\/pnas.0811073106","volume":"106","author":"M Ceppi","year":"2009","unstructured":"Ceppi, M. et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. USA 106, 2735\u20132740 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR186","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1182\/blood-2010-04-280156","volume":"116","author":"H Zhou","year":"2010","unstructured":"Zhou, H. et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 116, 5885\u20135894 (2010).","journal-title":"Blood"},{"key":"2168_CR187","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2045-3701-1-3","volume":"1","author":"CP Mao","year":"2011","unstructured":"Mao, C. P. et al. In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell Biosci. 1, 3 (2011).","journal-title":"Cell Biosci."},{"key":"2168_CR188","doi-asserted-by":"publisher","first-page":"16334","DOI":"10.1074\/jbc.M109.011601","volume":"284","author":"RT Martinez-Nunez","year":"2009","unstructured":"Martinez-Nunez, R. T., Louafi, F., Friedmann, P. S. & Sanchez-Elsner, T. MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). J. Biol. Chem. 284, 16334\u201316342 (2009).","journal-title":"J. Biol. Chem."},{"key":"2168_CR189","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1182\/blood-2010-09-308064","volume":"117","author":"I Dunand-Sauthier","year":"2011","unstructured":"Dunand-Sauthier, I. et al. Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood 117, 4490\u20134500 (2011).","journal-title":"Blood"},{"key":"2168_CR190","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.1141229","volume":"316","author":"TH Thai","year":"2007","unstructured":"Thai, T. H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604\u2013608 (2007).","journal-title":"Science"},{"key":"2168_CR191","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1126\/science.1139253","volume":"316","author":"A Rodriguez","year":"2007","unstructured":"Rodriguez, A. et al. Requirement of bic\/microRNA-155 for normal immune function. Science 316, 608\u2013611 (2007).","journal-title":"Science"},{"key":"2168_CR192","doi-asserted-by":"publisher","first-page":"e7158","DOI":"10.1371\/journal.pone.0007158","volume":"4","author":"HF Stahl","year":"2009","unstructured":"Stahl, H. F. et al. miR-155 inhibition sensitizes CD4+ Th cells for Treg mediated suppression. PLoS One 4, e7158 (2009).","journal-title":"PLoS One"},{"key":"2168_CR193","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2010.09.009","volume":"33","author":"RM O\u2019Connell","year":"2010","unstructured":"O\u2019Connell, R. M. et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33, 607\u2013619 (2010).","journal-title":"Immunity"},{"key":"2168_CR194","doi-asserted-by":"publisher","first-page":"e22444","DOI":"10.1097\/MD.0000000000022444","volume":"99","author":"Y Fan","year":"2020","unstructured":"Fan, Y. et al. Relationship of miRNA-146a to systemic lupus erythematosus: A PRISMA-compliant meta-analysis. Med. (Baltim.) 99, e22444 (2020).","journal-title":"Med. (Baltim.)"},{"key":"2168_CR195","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/gene.2011.84","volume":"13","author":"SE L\u00f6fgren","year":"2012","unstructured":"L\u00f6fgren, S. E. et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 13, 268\u2013274 (2012).","journal-title":"Genes Immun."},{"key":"2168_CR196","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1002\/art.39398","volume":"67","author":"B Qu","year":"2015","unstructured":"Qu, B. et al. Type I interferon inhibition of microRNA-146a maturation through up-regulation of monocyte chemotactic protein-induced protein 1 in systemic lupus erythematosus. Arthritis Rheumatol. 67, 3209\u20133218 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR197","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.1073\/pnas.0605298103","volume":"103","author":"KD Taganov","year":"2006","unstructured":"Taganov, K. D., Boldin, M. P., Chang, K. J. & Baltimore, D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12481\u201312486 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR198","doi-asserted-by":"publisher","first-page":"34590","DOI":"10.1074\/jbc.M109.056317","volume":"284","author":"MA Nahid","year":"2009","unstructured":"Nahid, M. A., Pauley, K. M., Satoh, M. & Chan, E. K. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J. Biol. Chem. 284, 34590\u201334599 (2009).","journal-title":"J. Biol. Chem."},{"key":"2168_CR199","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.4049\/jimmunol.1002311","volume":"186","author":"MA Nahid","year":"2011","unstructured":"Nahid, M. A., Satoh, M. & Chan, E. K. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J. Immunol. 186, 1723\u20131734 (2011).","journal-title":"J. Immunol."},{"key":"2168_CR200","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2010.08.012","volume":"142","author":"LF Lu","year":"2010","unstructured":"Lu, L. F. et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142, 914\u2013929 (2010).","journal-title":"Cell"},{"key":"2168_CR201","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2009-06-225987","volume":"115","author":"G Curtale","year":"2010","unstructured":"Curtale, G. et al. An emerging player in the adaptive immune response: MicroRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood 115, 265\u2013273 (2010).","journal-title":"Blood"},{"key":"2168_CR202","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nm.2266","volume":"17","author":"ED Ponomarev","year":"2011","unstructured":"Ponomarev, E. D., Veremeyko, T., Barteneva, N., Krichevsky, A. M. & Weiner, H. L. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C\/EBP-alpha-PU.1 pathway. Nat. Med. 17, 64\u201370 (2011).","journal-title":"Nat. Med."},{"key":"2168_CR203","doi-asserted-by":"publisher","first-page":"18704","DOI":"10.1073\/pnas.0905063106","volume":"106","author":"J Mattes","year":"2009","unstructured":"Mattes, J., Collison, A., Plank, M., Phipps, S. & Foster, P. S. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc. Natl. Acad. Sci. USA 106, 18704\u201318709 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR204","doi-asserted-by":"publisher","first-page":"28929","DOI":"10.1074\/jbc.M702633200","volume":"282","author":"XM Chen","year":"2007","unstructured":"Chen, X. M., Splinter, P. L., O\u2019Hara, S. P. & LaRusso, N. F. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J. Biol. Chem. 282, 28929\u201328938 (2007).","journal-title":"J. Biol. Chem."},{"key":"2168_CR205","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.4049\/jimmunol.1001937","volume":"187","author":"M Zhang","year":"2011","unstructured":"Zhang, M. et al. Inhibition of microRNA let-7i depresses maturation and functional state of dendritic cells in response to lipopolysaccharide stimulation via targeting suppressor of cytokine signaling 1. J. Immunol. 187, 1674\u20131683 (2011).","journal-title":"J. Immunol."},{"key":"2168_CR206","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1182\/blood-2008-09-181156","volume":"113","author":"RP Weitzel","year":"2009","unstructured":"Weitzel, R. P. et al. microRNA 184 regulates expression of NFAT1 in umbilical cord blood CD4\u2009+\u2009T cells. Blood 113, 6648\u20136657 (2009).","journal-title":"Blood"},{"key":"2168_CR207","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molimm.2010.10.021","volume":"48","author":"Q Xue","year":"2011","unstructured":"Xue, Q. et al. Human activated CD4(\u2009+\u2009) T lymphocytes increase IL-2 expression by downregulating microRNA-181c. Mol. Immunol. 48, 592\u2013599 (2011).","journal-title":"Mol. Immunol."},{"key":"2168_CR208","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/ni.1945","volume":"11","author":"AB Stittrich","year":"2010","unstructured":"Stittrich, A. B. et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat. Immunol. 11, 1057\u20131062 (2010).","journal-title":"Nat. Immunol."},{"key":"2168_CR209","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cell.2007.07.021","volume":"131","author":"C Xiao","year":"2007","unstructured":"Xiao, C. et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131, 146\u2013159 (2007).","journal-title":"Cell"},{"key":"2168_CR210","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1126\/science.1091903","volume":"303","author":"CZ Chen","year":"2004","unstructured":"Chen, C. Z., Li, L., Lodish, H. F. & Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83\u201386 (2004).","journal-title":"Science"},{"key":"2168_CR211","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cell.2007.03.008","volume":"129","author":"QJ Li","year":"2007","unstructured":"Li, Q. J. et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129, 147\u2013161 (2007).","journal-title":"Cell"},{"key":"2168_CR212","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1182\/blood-2010-12-325647","volume":"117","author":"Y Sun","year":"2011","unstructured":"Sun, Y. et al. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood 117, 6172\u20136183 (2011).","journal-title":"Blood"},{"key":"2168_CR213","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1002\/art.27632","volume":"62","author":"X Zhao","year":"2010","unstructured":"Zhao, X. et al. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 62, 3425\u20133435 (2010).","journal-title":"Arthritis Rheum."},{"key":"2168_CR214","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2249.1997.tb08326.x","volume":"110","author":"M Mizugaki","year":"1997","unstructured":"Mizugaki, M. et al. Alteration of DNA methylation levels in MRL lupus mice. Clin. Exp. Immunol. 110, 265\u2013269 (1997).","journal-title":"Clin. Exp. Immunol."},{"key":"2168_CR215","doi-asserted-by":"publisher","first-page":"7143","DOI":"10.4049\/jimmunol.176.12.7143","volume":"176","author":"E Ballestar","year":"2006","unstructured":"Ballestar, E., Esteller, M. & Richardson, B. C. The epigenetic face of systemic lupus erythematosus. J. Immunol. 176, 7143\u20137147 (2006).","journal-title":"J. Immunol."},{"key":"2168_CR216","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1172\/JCI116576","volume":"92","author":"J Quddus","year":"1993","unstructured":"Quddus, J. et al. Treating activated CD4\u2009+\u2009T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92, 38\u201353 (1993).","journal-title":"J. Clin. Invest."},{"key":"2168_CR217","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1172\/JCI118743","volume":"97","author":"R Yung","year":"1996","unstructured":"Yung, R. et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J. Clin. Invest 97, 2866\u20132871 (1996).","journal-title":"J. Clin. Invest"},{"key":"2168_CR218","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1136\/annrheumdis-2015-208410","volume":"75","author":"M Zhao","year":"2016","unstructured":"Zhao, M. et al. IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1998\u20132006 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR219","unstructured":"nmpa.gov.cn. IFI44L Gene Methylation Detection Kit (PCR-Melting Curve Method) approved for marketing, https:\/\/english.nmpa.gov.cn\/2024-02\/06\/c_986569.htm (2024)."},{"key":"2168_CR220","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.4049\/jimmunol.140.7.2197","volume":"140","author":"E Cornacchia","year":"1988","unstructured":"Cornacchia, E. et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140, 2197\u20132200 (1988).","journal-title":"J. Immunol."},{"key":"2168_CR221","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/art.10833","volume":"48","author":"C Deng","year":"2003","unstructured":"Deng, C. et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 48, 746\u2013756 (2003).","journal-title":"Arthritis Rheum."},{"key":"2168_CR222","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.4049\/jimmunol.179.8.5553","volume":"179","author":"G Gorelik","year":"2007","unstructured":"Gorelik, G., Fang, J. Y., Wu, A., Sawalha, A. H. & Richardson, B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J. Immunol. 179, 5553\u20135563 (2007).","journal-title":"J. Immunol."},{"key":"2168_CR223","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.4049\/jimmunol.0904060","volume":"184","author":"W Pan","year":"2010","unstructured":"Pan, W. et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4\u2009+\u2009T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 184, 6773\u20136781 (2010).","journal-title":"J. Immunol."},{"key":"2168_CR224","doi-asserted-by":"publisher","first-page":"12253","DOI":"10.1073\/pnas.2037852100","volume":"100","author":"FA Feltus","year":"2003","unstructured":"Feltus, F. A., Lee, E. K., Costello, J. F., Plass, C. & Vertino, P. M. Predicting aberrant CpG island methylation. Proc. Natl. Acad. Sci. USA 100, 12253\u201312258 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR225","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tibs.2005.12.008","volume":"31","author":"RJ Klose","year":"2006","unstructured":"Klose, R. J. & Bird, A. P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31, 89\u201397 (2006).","journal-title":"Trends Biochem. Sci."},{"key":"2168_CR226","doi-asserted-by":"publisher","first-page":"16916","DOI":"10.1073\/pnas.262443999","volume":"99","author":"F Chedin","year":"2002","unstructured":"Chedin, F., Lieber, M. R. & Hsieh, C. L. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc. Natl. Acad. Sci. USA 99, 16916\u201316921 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR227","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/jcb.20447","volume":"95","author":"ZX Chen","year":"2005","unstructured":"Chen, Z. X., Mann, J. R., Hsieh, C. L., Riggs, A. D. & Chedin, F. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. J. Cell Biochem. 95, 902\u2013917 (2005).","journal-title":"J. Cell Biochem."},{"key":"2168_CR228","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/gene.2008.29","volume":"9","author":"AH Sawalha","year":"2008","unstructured":"Sawalha, A. H. et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 9, 368\u2013378 (2008).","journal-title":"Genes Immun."},{"key":"2168_CR229","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/pr050188r","volume":"4","author":"BA Garcia","year":"2005","unstructured":"Garcia, B. A., Busby, S. A., Shabanowitz, J., Hunt, D. F. & Mishra, N. Resetting the epigenetic histone code in the MRL-lpr\/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res. 4, 2032\u20132042 (2005).","journal-title":"J. Proteome Res."},{"key":"2168_CR230","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/03009740902895750","volume":"38","author":"N Hu","year":"2009","unstructured":"Hu, N., Long, H., Zhao, M., Yin, H. & Lu, Q. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL\/lpr mice. Scand. J. Rheumatol. 38, 464\u2013471 (2009).","journal-title":"Scand. J. Rheumatol."},{"key":"2168_CR231","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1073\/pnas.051507098","volume":"98","author":"N Mishra","year":"2001","unstructured":"Mishra, N., Brown, D. R., Olorenshaw, I. M. & Kammer, G. M. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. USA 98, 2628\u20132633 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2168_CR232","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI16153","volume":"111","author":"N Mishra","year":"2003","unstructured":"Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. & Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse. J. Clin. Invest. 111, 539\u2013552 (2003).","journal-title":"J. Clin. Invest."},{"key":"2168_CR233","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.4049\/jimmunol.173.6.4171","volume":"173","author":"CM Reilly","year":"2004","unstructured":"Reilly, C. M. et al. Modulation of renal disease in MRL\/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173, 4171\u20134178 (2004).","journal-title":"J. Immunol."},{"key":"2168_CR234","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","volume":"294","author":"S Kovats","year":"2015","unstructured":"Kovats, S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 294, 63\u201369 (2015).","journal-title":"Cell Immunol."},{"key":"2168_CR235","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.steroids.2012.12.006","volume":"78","author":"K Ueda","year":"2013","unstructured":"Ueda, K. & Karas, R. H. Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system. Steroids 78, 589\u2013596 (2013).","journal-title":"Steroids"},{"key":"2168_CR236","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00026.2006","volume":"87","author":"N Heldring","year":"2007","unstructured":"Heldring, N. et al. Estrogen receptors: How do they signal and what are their targets. Physiol. Rev. 87, 905\u2013931 (2007).","journal-title":"Physiol. Rev."},{"key":"2168_CR237","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1091\/mbc.e03-06-0360","volume":"15","author":"MK Tee","year":"2004","unstructured":"Tee, M. K. et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol. Biol. Cell 15, 1262\u20131272 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"2168_CR238","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0606391","volume":"81","author":"AJ Lengi","year":"2007","unstructured":"Lengi, A. J., Phillips, R. A., Karpuzoglu, E. & Ahmed, S. A. Estrogen selectively regulates chemokines in murine splenocytes. J. Leukoc. Biol. 81, 1065\u20131074 (2007).","journal-title":"J. Leukoc. Biol."},{"key":"2168_CR239","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.immuni.2023.10.008","volume":"56","author":"JP Hoffmann","year":"2023","unstructured":"Hoffmann, J. P., Liu, J. A., Seddu, K. & Klein, S. L. Sex hormone signaling and regulation of immune function. Immunity 56, 2472\u20132491 (2023).","journal-title":"Immunity"},{"key":"2168_CR240","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/immu.200310027","volume":"33","author":"A Maret","year":"2003","unstructured":"Maret, A. et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur. J. Immunol. 33, 512\u2013521 (2003).","journal-title":"Eur. J. Immunol."},{"key":"2168_CR241","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.4049\/jimmunol.168.10.5369","volume":"168","author":"M Bao","year":"2002","unstructured":"Bao, M., Yang, Y., Jun, H. S. & Yoon, J. W. Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 168, 5369\u20135375 (2002).","journal-title":"J. Immunol."},{"key":"2168_CR242","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4049\/jimmunol.158.1.446","volume":"158","author":"W Gilmore","year":"1997","unstructured":"Gilmore, W., Weiner, L. P. & Correale, J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J. Immunol. 158, 446\u2013451 (1997).","journal-title":"J. Immunol."},{"key":"2168_CR243","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0165-5728(02)00016-4","volume":"124","author":"YC Zang","year":"2002","unstructured":"Zang, Y. C., Halder, J. B., Hong, J., Rivera, V. M. & Zhang, J. Z. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J. Neuroimmunol. 124, 106\u2013114 (2002).","journal-title":"J. Neuroimmunol."},{"key":"2168_CR244","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1210\/rp.57.1.435","volume":"57","author":"LY Yu-Lee","year":"2002","unstructured":"Yu-Lee, L. Y. Prolactin modulation of immune and inflammatory responses. Recent. Prog. Horm. Res. 57, 435\u2013455 (2002).","journal-title":"Recent. Prog. Horm. Res."},{"key":"2168_CR245","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0165-5728(93)90282-4","volume":"47","author":"N Lahat","year":"1993","unstructured":"Lahat, N., Miller, A., Shtiller, R. & Touby, E. Differential effects of prolactin upon activation and differentiation of human B lymphocytes. J. Neuroimmunol. 47, 35\u201340 (1993).","journal-title":"J. Neuroimmunol."},{"key":"2168_CR246","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1677\/joe.0.1470353","volume":"147","author":"MC Leite-de-Moraes","year":"1995","unstructured":"Leite-de-Moraes, M. C., Touraine, P., Kelly, P. A., Kuttenn, F. & Dardenne, M. Prolactin receptor expression in lymphocytes from patients with hyperprolactinemia or acromegaly. J. Endocrinol. 147, 353\u2013359 (1995).","journal-title":"J. Endocrinol."},{"key":"2168_CR247","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3899\/jrheum.200002","volume":"48","author":"D Dominguez","year":"2021","unstructured":"Dominguez, D. et al. Relationship between genetic risk and age of diagnosis in systemic lupus erythematosus. J. Rheumatol. 48, 852\u2013858 (2021).","journal-title":"J. Rheumatol."},{"key":"2168_CR248","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/ard.2010.141697","volume":"70","author":"R Webb","year":"2011","unstructured":"Webb, R. et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann. Rheum. Dis. 70, 151\u2013156 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR249","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4049\/jimmunol.172.2.1287","volume":"172","author":"I Kang","year":"2004","unstructured":"Kang, I. et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 172, 1287\u20131294 (2004).","journal-title":"J. Immunol."},{"key":"2168_CR250","doi-asserted-by":"publisher","first-page":"e14488","DOI":"10.1371\/journal.pone.0014488","volume":"6","author":"P Yadav","year":"2011","unstructured":"Yadav, P. et al. Antibodies elicited in response to EBNA-1 may cross-react with dsDNA. PLoS One 6, e14488 (2011).","journal-title":"PLoS One"},{"key":"2168_CR251","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/01.bor.0000240355.37927.94","volume":"18","author":"JA James","year":"2006","unstructured":"James, J. A., Harley, J. B. & Scofield, R. H. Epstein-Barr virus and systemic lupus erythematosus. Curr. Opin. Rheumatol. 18, 462\u2013467 (2006).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2168_CR252","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/ar4429","volume":"16","author":"P Hanlon","year":"2014","unstructured":"Hanlon, P., Avenell, A., Aucott, L. & Vickers, M. A. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res. Ther. 16, R3 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"2168_CR253","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.kint.2022.01.013","volume":"101","author":"HJ Kim","year":"2022","unstructured":"Kim, H. J., Jung, M., Lim, B. J. & Han, S. H. New-onset class III lupus nephritis with multi-organ involvement after COVID-19 vaccination. Kidney Int 101, 826\u2013828 (2022).","journal-title":"Kidney Int"},{"key":"2168_CR254","doi-asserted-by":"crossref","unstructured":"Nune, A. et al. New-onset rheumatic immune-mediated inflammatory diseases following SARS-CoV-2 vaccinations until May 2023: A systematic review. Vaccines (Basel) 11, 1571 (2023).","DOI":"10.3390\/vaccines11101571"},{"key":"2168_CR255","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.kint.2021.09.009","volume":"100","author":"MF Zavala-Miranda","year":"2021","unstructured":"Zavala-Miranda, M. F., Gonz\u00e1lez-Ibarra, S. G., P\u00e9rez-Arias, A. A., Uribe-Uribe, N. O. & Mejia-Vilet, J. M. New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination. Kidney Int. 100, 1340\u20131341 (2021).","journal-title":"Kidney Int."},{"key":"2168_CR256","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.kint.2021.07.019","volume":"100","author":"K Tuschen","year":"2021","unstructured":"Tuschen, K., Br\u00e4sen, J. H., Schmitz, J., Vischedyk, M. & Weidemann, A. Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine. Kidney Int 100, 941\u2013944 (2021).","journal-title":"Kidney Int"},{"key":"2168_CR257","doi-asserted-by":"publisher","first-page":"eabj7211","DOI":"10.1126\/scitranslmed.abj7211","volume":"13","author":"PA Swanson 2nd","year":"2021","unstructured":"Swanson, P. A. 2nd et al. AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T(H)1 response with a diverse TCR repertoire. Sci. Transl. Med 13, eabj7211 (2021).","journal-title":"Sci. Transl. Med"},{"key":"2168_CR258","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-023-01485-6","volume":"8","author":"G Li","year":"2023","unstructured":"Li, G. et al. Enhancement of SARS-CoV-2 vaccine-induced immunity by a Toll-like receptor 7 agonist adjuvant. Signal Transduct. Target Ther. 8, 213 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2168_CR259","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1021\/acsnano.3c09700","volume":"18","author":"BS Ou","year":"2024","unstructured":"Ou, B. S. et al. Nanoparticle-conjugated Toll-like receptor 9 agonists improve the potency, durability, and breadth of COVID-19 vaccines. ACS Nano 18, 3214\u20133233 (2024).","journal-title":"ACS Nano"},{"key":"2168_CR260","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2133.2003.05379.x","volume":"149","author":"CJ Sanders","year":"2003","unstructured":"Sanders, C. J. et al. Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br. J. Dermatol. 149, 131\u2013137 (2003).","journal-title":"Br. J. Dermatol."},{"key":"2168_CR261","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/art.40372","volume":"70","author":"JA Irizarry-Caro","year":"2018","unstructured":"Irizarry-Caro, J. A. et al. Brief report: Drugs implicated in systemic autoimmunity modulate neutrophil extracellular trap formation. Arthritis Rheumatol. 70, 468\u2013474 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR262","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","volume":"17","author":"A Vaglio","year":"2018","unstructured":"Vaglio, A. et al. Drug-induced lupus: traditional and new concepts. Autoimmun. Rev. 17, 912\u2013918 (2018).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR263","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41584-018-0039-z","volume":"14","author":"F Apel","year":"2018","unstructured":"Apel, F., Zychlinsky, A. & Kenny, E. F. The role of neutrophil extracellular traps in rheumatic diseases. Nat. Rev. Rheumatol. 14, 467\u2013475 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR264","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2796.1990.tb00144.x","volume":"227","author":"LE R\u00f6nnblom","year":"1990","unstructured":"R\u00f6nnblom, L. E., Alm, G. V. & Oberg, K. E. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 227, 207\u2013210 (1990).","journal-title":"J. Intern. Med."},{"key":"2168_CR265","doi-asserted-by":"publisher","first-page":"1223062","DOI":"10.3389\/fimmu.2023.1223062","volume":"14","author":"Z Zeng","year":"2023","unstructured":"Zeng, Z. et al. IFN-\u03b1 induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review. Front. Immunol. 14, 1223062 (2023).","journal-title":"Front. Immunol."},{"key":"2168_CR266","first-page":"223","volume":"26","author":"R Khalil Ur","year":"2016","unstructured":"Khalil Ur, R. & Khokhar, N. Development of Systemic Lupus Erythematosus Following Interferon-\u03b1 Therapy for Hepatitis C Infection. J. Coll. Physicians Surg. Pak. 26, 223\u2013224 (2016).","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"2168_CR267","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/art.20049","volume":"50","author":"KH Costenbader","year":"2004","unstructured":"Costenbader, K. H. et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum. 50, 849\u2013857 (2004).","journal-title":"Arthritis Rheum."},{"key":"2168_CR268","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S1734-1140(11)70402-9","volume":"63","author":"O Mathieu","year":"2011","unstructured":"Mathieu, O. et al. Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-\u03b3 secretion in epileptic patients: the influence of co-medication. Pharmacol. Rep. 63, 86\u201394 (2011).","journal-title":"Pharmacol. Rep."},{"key":"2168_CR269","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1046\/j.1365-2567.1999.00849.x","volume":"98","author":"BY Kang","year":"1999","unstructured":"Kang, B. Y., Chung, S. W., Im, S. Y., Choe, Y. K. & Kim, T. S. Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology 98, 98\u2013103 (1999).","journal-title":"Immunology"},{"key":"2168_CR270","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1186\/ar3546","volume":"13","author":"N Yukawa","year":"2011","unstructured":"Yukawa, N. et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res. Ther. 13, R213 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"2168_CR271","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1136\/annrheumdis-2014-205318","volume":"73","author":"K Takase","year":"2014","unstructured":"Takase, K. et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann. Rheum. Dis. 73, 1695\u20131699 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR272","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/scrt228","volume":"4","author":"Y Hou","year":"2013","unstructured":"Hou, Y. et al. Effective combination of human bone marrow mesenchymal stem cells and minocycline in experimental autoimmune encephalomyelitis mice. Stem Cell Res. Ther. 4, 77 (2013).","journal-title":"Stem Cell Res. Ther."},{"key":"2168_CR273","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/exd.13779","volume":"27","author":"K Tanita","year":"2018","unstructured":"Tanita, K., Fujimura, T., Sato, Y., Lyu, C. & Aiba, S. Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs. Exp. Dermatol. 27, 1268\u20131272 (2018).","journal-title":"Exp. Dermatol."},{"key":"2168_CR274","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/BOR.0000000000000318","volume":"28","author":"M Barbhaiya","year":"2016","unstructured":"Barbhaiya, M. & Costenbader, K. H. Environmental exposures and the development of systemic lupus erythematosus. Curr. Opin. Rheumatol. 28, 497\u2013505 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2168_CR275","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/joim.13448","volume":"291","author":"JMP Woo","year":"2022","unstructured":"Woo, J. M. P., Parks, C. G., Jacobsen, S., Costenbader, K. H. & Bernatsky, S. The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous. J. Intern. Med. 291, 755\u2013778 (2022).","journal-title":"J. Intern. Med."},{"key":"2168_CR276","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/IJWH.S90157","volume":"8","author":"Y Yamamoto","year":"2016","unstructured":"Yamamoto, Y. & Aoki, S. Systemic lupus erythematosus: strategies to improve pregnancy outcomes. Int. J. Women\u2019s Health 8, 265\u2013272 (2016).","journal-title":"Int. J. Women\u2019s Health"},{"key":"2168_CR277","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/art.41935","volume":"74","author":"MY Choi","year":"2022","unstructured":"Choi, M. Y. et al. Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus. Arthritis Rheumatol. 74, 274\u2013283 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR278","first-page":"1928","volume":"31","author":"GS Cooper","year":"2004","unstructured":"Cooper, G. S. et al. Occupational risk factors for the development of systemic lupus erythematosus. J. Rheumatol. 31, 1928\u20131933 (2004).","journal-title":"J. Rheumatol."},{"key":"2168_CR279","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/acr.20335","volume":"63","author":"CG Parks","year":"2011","unstructured":"Parks, C. G. et al. Insecticide use and risk of rheumatoid arthritis and systemic lupus erythematosus in the women\u2019s health initiative observational study. Arthritis Care Res. (Hoboken) 63, 184\u2013194 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR280","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1177\/0961203318805844","volume":"27","author":"JN Williams","year":"2018","unstructured":"Williams, J. N. et al. Pesticide exposure and risk of systemic lupus erythematosus in an urban population of predominantly African-American women. Lupus 27, 2129\u20132134 (2018).","journal-title":"Lupus"},{"key":"2168_CR281","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/ije\/dyaa287","volume":"50","author":"SH Boudigaard","year":"2021","unstructured":"Boudigaard, S. H. et al. Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study. Int. J. Epidemiol. 50, 1213\u20131226 (2021).","journal-title":"Int. J. Epidemiol."},{"key":"2168_CR282","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1002\/art.10368","volume":"46","author":"CG Parks","year":"2002","unstructured":"Parks, C. G. et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: A population-based, case-control study in the southeastern United States. Arthritis Rheum. 46, 1840\u20131850 (2002).","journal-title":"Arthritis Rheum."},{"key":"2168_CR283","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1002\/art.22210","volume":"54","author":"A Finckh","year":"2006","unstructured":"Finckh, A. et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum. 54, 3648\u20133654 (2006).","journal-title":"Arthritis Rheum."},{"key":"2168_CR284","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/rheumatology\/keq214","volume":"49","author":"GS Cooper","year":"2010","unstructured":"Cooper, G. S. et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatol. (Oxf.) 49, 2172\u20132180 (2010).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR285","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.envres.2015.12.021","volume":"146","author":"S Bernatsky","year":"2016","unstructured":"Bernatsky, S. et al. Fine particulate air pollution and systemic autoimmune rheumatic disease in two Canadian provinces. Environ. Res. 146, 85\u201391 (2016).","journal-title":"Environ. Res."},{"key":"2168_CR286","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.envres.2015.05.007","volume":"140","author":"S Bernatsky","year":"2015","unstructured":"Bernatsky, S. et al. Fine particulate air pollution, nitrogen dioxide, and systemic autoimmune rheumatic disease in Calgary, Alberta. Environ. Res. 140, 474\u2013478 (2015).","journal-title":"Environ. Res."},{"key":"2168_CR287","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1084\/jem.20081761","volume":"206","author":"D Iwakiri","year":"2009","unstructured":"Iwakiri, D. et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J. Exp. Med. 206, 2091\u20132099 (2009).","journal-title":"J. Exp. Med."},{"key":"2168_CR288","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.39987","volume":"69","author":"C Sontheimer","year":"2017","unstructured":"Sontheimer, C., Liggitt, D. & Elkon, K. B. Ultraviolet B irradiation causes stimulator of interferon genes-dependent production of protective type I interferon in mouse skin by recruited inflammatory monocytes. Arthritis Rheumatol. 69, 826\u2013836 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR289","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/08916934.2013.866105","volume":"47","author":"Q Yin","year":"2014","unstructured":"Yin, Q. et al. Ultraviolet B irradiation induces skin accumulation of plasmacytoid dendritic cells: a possible role for chemerin. Autoimmunity 47, 185\u2013192 (2014).","journal-title":"Autoimmunity"},{"key":"2168_CR290","doi-asserted-by":"publisher","first-page":"102291","DOI":"10.1016\/j.jaut.2019.06.002","volume":"103","author":"SJ Wolf","year":"2019","unstructured":"Wolf, S. J. et al. Ultraviolet light induces increased T cell activation in lupus-prone mice via type I IFN-dependent inhibition of T regulatory cells. J. Autoimmun. 103, 102291 (2019).","journal-title":"J. Autoimmun."},{"key":"2168_CR291","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2009.12.053","volume":"64","author":"A Kuhn","year":"2011","unstructured":"Kuhn, A. et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J. Am. Acad. Dermatol. 64, 37\u201348 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2168_CR292","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/exd.12035","volume":"21","author":"N Patsinakidis","year":"2012","unstructured":"Patsinakidis, N. et al. Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls. Exp. Dermatol. 21, 958\u2013961 (2012).","journal-title":"Exp. Dermatol."},{"key":"2168_CR293","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-319-56017-5_12","volume":"996","author":"MF Holick","year":"2017","unstructured":"Holick, M. F. Ultraviolet B radiation: the vitamin D connection. Adv. Exp. Med. Biol. 996, 137\u2013154 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2168_CR294","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/ard.2007.072736","volume":"67","author":"KH Costenbader","year":"2008","unstructured":"Costenbader, K. H., Feskanich, D., Holmes, M., Karlson, E. W. & Benito-Garcia, E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann. Rheum. Dis. 67, 530\u2013535 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR295","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/art.38429","volume":"66","author":"L Grimaldi-Bensouda","year":"2014","unstructured":"Grimaldi-Bensouda, L. et al. The risk of systemic lupus erythematosus associated with vaccines: an international case-control study. Arthritis Rheumatol. 66, 1559\u20131567 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR296","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.06.014","volume":"75","author":"D Clayton-Chubb","year":"2021","unstructured":"Clayton-Chubb, D., Schneider, D., Freeman, E., Kemp, W. & Roberts, S. K. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine. J. Hepatol. 75, 1249\u20131250 (2021).","journal-title":"J. Hepatol."},{"key":"2168_CR297","doi-asserted-by":"publisher","first-page":"102941","DOI":"10.1016\/j.autrev.2021.102941","volume":"20","author":"F Elrashdy","year":"2021","unstructured":"Elrashdy, F. et al. Autoimmunity roots of the thrombotic events after COVID-19 vaccination. Autoimmun. Rev. 20, 102941 (2021).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR298","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/1756-185X.14220","volume":"24","author":"C Baimukhamedov","year":"2021","unstructured":"Baimukhamedov, C., Makhmudov, S. & Botabekova, A. Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection. Int. J. Rheum. Dis. 24, 1440\u20131441 (2021).","journal-title":"Int. J. Rheum. Dis."},{"key":"2168_CR299","doi-asserted-by":"publisher","first-page":"102951","DOI":"10.1016\/j.autrev.2021.102951","volume":"20","author":"L Badier","year":"2021","unstructured":"Badier, L. et al. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun. Rev. 20, 102951 (2021).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR300","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","volume":"165","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 165, 386\u2013401 (2022).","journal-title":"Immunology"},{"key":"2168_CR301","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1111\/jocd.14386","volume":"20","author":"S Patil","year":"2021","unstructured":"Patil, S. & Patil, A. Systemic lupus erythematosus after COVID-19 vaccination: a case report. J. Cosmet. Dermatol. 20, 3103\u20133104 (2021).","journal-title":"J. Cosmet. Dermatol."},{"key":"2168_CR302","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1111\/jdv.17514","volume":"35","author":"A Kreuter","year":"2021","unstructured":"Kreuter, A., Burmann, S. N., Burkert, B., Oellig, F. & Michalowitz, A. L. Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination. J. Eur. Acad. Dermatol. Venereol. 35, e733\u2013e735 (2021).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2168_CR303","doi-asserted-by":"publisher","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui, X. & Snapper, C. M. Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front. Immunol. 12, 734471 (2021).","journal-title":"Front. Immunol."},{"key":"2168_CR304","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2017-211675","volume":"77","author":"M Barbhaiya","year":"2018","unstructured":"Barbhaiya, M. et al. Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses\u2019 Health Study cohorts. Ann. Rheum. Dis. 77, 196\u2013202 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR305","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/acr.23703","volume":"71","author":"YC Cozier","year":"2019","unstructured":"Cozier, Y. C. et al. Relationship of cigarette smoking and alcohol consumption to incidence of systemic lupus erythematosus in a prospective cohort study of black women. Arthritis Care Res. (Hoboken) 71, 671\u2013677 (2019).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR306","doi-asserted-by":"crossref","unstructured":"Morissette, M. C. et al. Role of BAFF in pulmonary autoantibody responses induced by chronic cigarette smoke exposure in mice. Physiol. Rep. 4 (2016).","DOI":"10.14814\/phy2.13057"},{"key":"2168_CR307","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/art.39427","volume":"68","author":"RA Montes","year":"2016","unstructured":"Montes, R. A. et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the systemic lupus international collaborating clinics\/American college of rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 68, 441\u2013448 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR308","first-page":"4122","volume":"58","author":"S Petruzzelli","year":"1998","unstructured":"Petruzzelli, S. et al. Serum antibodies to benzo(a)pyrene diol epoxide-DNA adducts in the general population: effects of air pollution, tobacco smoking, and family history of lung diseases. Cancer Res. 58, 4122\u20134126 (1998).","journal-title":"Cancer Res."},{"key":"2168_CR309","first-page":"641","volume":"10","author":"LA Mooney","year":"2001","unstructured":"Mooney, L. A. et al. Gender differences in autoantibodies to oxidative DNA base damage in cigarette smokers. Cancer Epidemiol. Biomark. Prev. 10, 641\u2013648 (2001).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"2168_CR310","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0002-9149(02)02284-1","volume":"89","author":"EA Bermudez","year":"2002","unstructured":"Bermudez, E. A., Rifai, N., Buring, J. E., Manson, J. E. & Ridker, P. M. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol. 89, 1117\u20131119 (2002).","journal-title":"Am. J. Cardiol."},{"key":"2168_CR311","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/acr.24370","volume":"73","author":"J Hahn","year":"2021","unstructured":"Hahn, J. et al. Associations between smoking and systemic lupus erythematosus-related cytokines and chemokines among US female nurses. Arthritis Care Res. (Hoboken) 73, 1583\u20131589 (2021).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR312","doi-asserted-by":"publisher","first-page":"R1527","DOI":"10.1152\/ajpregu.00186.2006","volume":"291","author":"BD Palma","year":"2006","unstructured":"Palma, B. D., Gabriel, A. Jr., Colugnati, F. A. & Tufik, S. Effects of sleep deprivation on the development of autoimmune disease in an experimental model of systemic lupus erythematosus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R1527\u2013R1532 (2006).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2168_CR313","doi-asserted-by":"publisher","first-page":"581","DOI":"10.5665\/sleep.4574","volume":"38","author":"YH Hsiao","year":"2015","unstructured":"Hsiao, Y. H. et al. Sleep disorders and increased risk of autoimmune diseases in individuals without sleep apnea. Sleep 38, 581\u2013586 (2015).","journal-title":"Sleep"},{"key":"2168_CR314","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0961203318778368","volume":"27","author":"KA Young","year":"2018","unstructured":"Young, K. A. et al. Less than 7\u2009hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27, 1524\u20131531 (2018).","journal-title":"Lupus"},{"key":"2168_CR315","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/acr.25017","volume":"75","author":"MY Choi","year":"2023","unstructured":"Choi, M. Y. et al. Association of sleep deprivation and the risk of developing systemic lupus erythematosus among women. Arthritis Care Res. (Hoboken) 75, 1206\u20131212 (2023).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR316","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2005.03.010","volume":"183","author":"DB Panagiotakos","year":"2005","unstructured":"Panagiotakos, D. B., Pitsavos, C., Yannakoulia, M., Chrysohoou, C. & Stefanadis, C. The implication of obesity and central fat on markers of chronic inflammation: The ATTICA study. Atherosclerosis 183, 308\u2013315 (2005).","journal-title":"Atherosclerosis"},{"key":"2168_CR317","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/met.2015.0095","volume":"13","author":"P Manna","year":"2015","unstructured":"Manna, P. & Jain, S. K. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab. Syndr. Relat. Disord. 13, 423\u2013444 (2015).","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"2168_CR318","doi-asserted-by":"publisher","first-page":"e15214","DOI":"10.1111\/1756-185X.15214","volume":"27","author":"AF Huang","year":"2024","unstructured":"Huang, A. F., Zhou, L. & Xu, W. D. The causal associations of inflammatory cytokines with obesity and systemic lupus erythematosus: A Mendelian randomization study. Int. J. Rheum. Dis. 27, e15214 (2024).","journal-title":"Int. J. Rheum. Dis."},{"key":"2168_CR319","doi-asserted-by":"publisher","first-page":"696810","DOI":"10.3389\/fimmu.2021.696810","volume":"12","author":"AL Schafer","year":"2021","unstructured":"Schafer, A. L. et al. Low dietary fiber intake links development of obesity and lupus pathogenesis. Front. Immunol. 12, 696810 (2021).","journal-title":"Front. Immunol."},{"key":"2168_CR320","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/ajcn\/nqab224","volume":"114","author":"N Castro-Webb","year":"2021","unstructured":"Castro-Webb, N. et al. Association of macronutrients and dietary patterns with risk of systemic lupus erythematosus in the Black Women\u2019s Health Study. Am. J. Clin. Nutr. 114, 1486\u20131494 (2021).","journal-title":"Am. J. Clin. Nutr."},{"key":"2168_CR321","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/acr.24188","volume":"73","author":"YC Cozier","year":"2021","unstructured":"Cozier, Y. C. et al. Association of child abuse and systemic lupus erythematosus in black women during adulthood. Arthritis Care Res. (Hoboken) 73, 833\u2013840 (2021).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR322","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3899\/jrheum.190009","volume":"46","author":"CH Feldman","year":"2019","unstructured":"Feldman, C. H. et al. Association of childhood abuse with incident systemic lupus erythematosus in adulthood in a longitudinal cohort of women. J. Rheumatol. 46, 1589\u20131596 (2019).","journal-title":"J. Rheumatol."},{"key":"2168_CR323","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1002\/art.40222","volume":"69","author":"AL Roberts","year":"2017","unstructured":"Roberts, A. L. et al. Association of trauma and posttraumatic stress disorder with incident systemic lupus erythematosus in a longitudinal cohort of women. Arthritis Rheumatol. 69, 2162\u20132169 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR324","doi-asserted-by":"crossref","unstructured":"DeQuattro, K. et al. Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history. Lupus Sci. Med. 11 (2024).","DOI":"10.1136\/lupus-2023-001060"},{"key":"2168_CR325","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamapsychiatry.2018.2462","volume":"75","author":"AL Roberts","year":"2018","unstructured":"Roberts, A. L., Kubzansky, L. D., Malspeis, S., Feldman, C. H. & Costenbader, K. H. Association of depression with risk of incident systemic lupus erythematosus in women assessed across 2 decades. JAMA Psychiatry 75, 1225\u20131233 (2018).","journal-title":"JAMA Psychiatry"},{"key":"2168_CR326","doi-asserted-by":"crossref","unstructured":"Yang, L. et al. Association of disease activity with depression and anxiety in systemic lupus erythematosus: A comparison of SLEDAI-2K and SLE-DAS. Rheumatology (Oxford) 64, 632\u2013638 (2025).","DOI":"10.1093\/rheumatology\/keae070"},{"key":"2168_CR327","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1196\/annals.1351.006","volume":"1069","author":"E Calcagni","year":"2006","unstructured":"Calcagni, E. & Elenkov, I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann. N. Y. Acad. Sci. 1069, 62\u201376 (2006).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2168_CR328","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1172\/JCI0214873","volume":"109","author":"CM Grimaldi","year":"2002","unstructured":"Grimaldi, C. M., Cleary, J., Dagtas, A. S., Moussai, D. & Diamond, B. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 109, 1625\u20131633 (2002).","journal-title":"J. Clin. Invest."},{"key":"2168_CR329","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.24398","volume":"61","author":"MO Bernier","year":"2009","unstructured":"Bernier, M. O., Mikaeloff, Y., Hudson, M. & Suissa, S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum. 61, 476\u2013481 (2009).","journal-title":"Arthritis Rheum."},{"key":"2168_CR330","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/art.22510","volume":"56","author":"KH Costenbader","year":"2007","unstructured":"Costenbader, K. H., Feskanich, D., Stampfer, M. J. & Karlson, E. W. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 56, 1251\u20131262 (2007).","journal-title":"Arthritis Rheum."},{"key":"2168_CR331","doi-asserted-by":"publisher","first-page":"J170","DOI":"10.1016\/j.jaut.2011.11.002","volume":"38","author":"A Lateef","year":"2012","unstructured":"Lateef, A. & Petri, M. Hormone replacement and contraceptive therapy in autoimmune diseases. J. Autoimmun. 38, J170\u2013J176 (2012).","journal-title":"J. Autoimmun."},{"key":"2168_CR332","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/09612033231180358","volume":"32","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. The causal effects of age at menarche, age at first live birth, and estradiol levels on systemic lupus erythematosus: A two-sample Mendelian randomization analysis. Lupus 32, 928\u2013935 (2023).","journal-title":"Lupus"},{"key":"2168_CR333","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","volume":"119","author":"A Doria","year":"2006","unstructured":"Doria, A. et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med. 119, 700\u2013706 (2006).","journal-title":"Am. J. Med."},{"key":"2168_CR334","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","volume":"10","author":"V Bouvard","year":"2009","unstructured":"Bouvard, V. et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 10, 321\u2013322 (2009).","journal-title":"Lancet Oncol."},{"key":"2168_CR335","doi-asserted-by":"crossref","unstructured":"Chau, S. L. et al. Distinct molecular landscape of Epstein-Barr virus associated pulmonary lymphoepithelioma-like carcinoma revealed by genomic sequencing. Cancers (Basel) 12, 2065 (2020).","DOI":"10.3390\/cancers12082065"},{"key":"2168_CR336","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10902-w","volume":"10","author":"S Hong","year":"2019","unstructured":"Hong, S. et al. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat. Commun. 10, 3108 (2019).","journal-title":"Nat. Commun."},{"key":"2168_CR337","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","volume":"23","author":"SG Fisher","year":"2004","unstructured":"Fisher, S. G. & Fisher, R. I. The epidemiology of non-Hodgkin\u2019s lymphoma. Oncogene 23, 6524\u20136534 (2004).","journal-title":"Oncogene"},{"key":"2168_CR338","first-page":"e609","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer, M. et al. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob. Health 4, e609\u2013e616 (2016).","journal-title":"Health"},{"key":"2168_CR339","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1002\/art.30483","volume":"63","author":"L Dreyer","year":"2011","unstructured":"Dreyer, L., Faurschou, M., Mogensen, M. & Jacobsen, S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum. 63, 3032\u20133037 (2011).","journal-title":"Arthritis Rheum."},{"key":"2168_CR340","doi-asserted-by":"publisher","first-page":"e29088","DOI":"10.1002\/jmv.29088","volume":"95","author":"X Yao","year":"2023","unstructured":"Yao, X. et al. Role of human papillomavirus and associated viruses in bladder cancer: An updated review. J. Med. Virol. 95, e29088 (2023).","journal-title":"J. Med. Virol."},{"key":"2168_CR341","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/hon.2270","volume":"35","author":"S Intaraphet","year":"2017","unstructured":"Intaraphet, S., Farkas, D. K., Johannesdottir Schmidt, S. A., Cronin-Fenton, D. & Sogaard, M. Human papillomavirus infection and lymphoma incidence using cervical conization as a surrogate marker: a Danish nationwide cohort study. Hematol. Oncol. 35, 172\u2013176 (2017).","journal-title":"Hematol. Oncol."},{"key":"2168_CR342","doi-asserted-by":"crossref","unstructured":"Goulenok, T. et al. Improving human papillomavirus-related cervical cancer screening in patients with systemic lupus erythematosus. J. Rheumatol. 50, 1642\u20131644 (2023).","DOI":"10.3899\/jrheum.2022-1335"},{"key":"2168_CR343","first-page":"45","volume":"33","author":"SR Bernatsky","year":"2006","unstructured":"Bernatsky, S. R. et al. Cancer screening in patients with systemic lupus erythematosus. J. Rheumatol. 33, 45\u201349 (2006).","journal-title":"J. Rheumatol."},{"key":"2168_CR344","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1310\/RWG0-49RM-GQH4-5BB3","volume":"2","author":"Panel on Clinical Practices for Treatment of, H. I. V. I.","year":"2001","unstructured":"Panel on Clinical Practices for Treatment of, H. I. V. I. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. HIV Clin. Trials 2, 227\u2013306 (2001). February 5, 2001.","journal-title":"HIV Clin. Trials"},{"key":"2168_CR345","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.det.2008.07.011","volume":"27","author":"JQ Del Rosso","year":"2009","unstructured":"Del Rosso, J. Q. Oral antibiotic drug interactions of clinical significance to dermatologists. Dermatol. Clin. 27, 91\u201394 (2009).","journal-title":"Dermatol. Clin."},{"key":"2168_CR346","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 52, e56\u2013e93 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"2168_CR347","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41584-020-0462-9","volume":"16","author":"J McHugh","year":"2020","unstructured":"McHugh, J. Targeted delivery of immunosuppressant in SLE. Nat. Rev. Rheumatol. 16, 410 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR348","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736\u2013745 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR349","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233\u2013247 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"2168_CR350","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1111\/j.1365-2893.2010.01430.x","volume":"18","author":"JF Moller","year":"2011","unstructured":"Moller, J. F., Moller, B., Wiedenmann, B., Berg, T. & Schott, E. CD154, a marker of antigen-specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection. J. Viral Hepat. 18, e341\u2013e349 (2011).","journal-title":"J. Viral Hepat."},{"key":"2168_CR351","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier, E. & Dorner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155\u2013166 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR352","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.2174\/0929867327666201006153202","volume":"28","author":"J Patocka","year":"2021","unstructured":"Patocka, J., Nepovimova, E., Kuca, K. & Wu, W. Cyclosporine A: chemistry and toxicity - a review. Curr. Med. Chem. 28, 3925\u20133934 (2021).","journal-title":"Curr. Med. Chem."},{"key":"2168_CR353","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.24328","volume":"72","author":"M Barbhaiya","year":"2020","unstructured":"Barbhaiya, M. et al. Comparative risks of cardiovascular disease in patients with systemic lupus erythematosus, diabetes mellitus, and in general medicaid recipients. Arthritis Care Res. (Hoboken) 72, 1431\u20131439 (2020).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR354","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1177\/0961203318804883","volume":"27","author":"SY Lim","year":"2018","unstructured":"Lim, S. Y. et al. Systemic lupus erythematosus is a risk factor for cardiovascular disease: a nationwide, population-based study in Korea. Lupus 27, 2050\u20132056 (2018).","journal-title":"Lupus"},{"key":"2168_CR355","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0002-9343(75)90575-6","volume":"58","author":"BH Bulkley","year":"1975","unstructured":"Bulkley, B. H. & Roberts, W. C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am. J. Med. 58, 243\u2013264 (1975).","journal-title":"Am. J. Med."},{"key":"2168_CR356","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/0002-9343(81)90532-5","volume":"70","author":"YS Haider","year":"1981","unstructured":"Haider, Y. S. & Roberts, W. C. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am. J. Med. 70, 775\u2013781 (1981).","journal-title":"Am. J. Med."},{"key":"2168_CR357","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1161\/01.CIR.103.22.2705","volume":"103","author":"EM Tuzcu","year":"2001","unstructured":"Tuzcu, E. M. et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103, 2705\u20132710 (2001).","journal-title":"Circulation"},{"key":"2168_CR358","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/annrheumdis-2017-212614","volume":"77","author":"D Leonard","year":"2018","unstructured":"Leonard, D. et al. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum. Dis. 77, 1063\u20131069 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR359","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1177\/2047487314546826","volume":"22","author":"F Ballocca","year":"2015","unstructured":"Ballocca, F. et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 22, 1435\u20131441 (2015).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2168_CR360","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1191\/096120300678828208","volume":"9","author":"C Aranow","year":"2000","unstructured":"Aranow, C. & Ginzler, E. M. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9, 166\u2013169 (2000).","journal-title":"Lupus"},{"key":"2168_CR361","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","volume":"145","author":"S Manzi","year":"1997","unstructured":"Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408\u2013415 (1997).","journal-title":"Am. J. Epidemiol."},{"key":"2168_CR362","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2478\/rir-2021-0022","volume":"2","author":"M McMahon","year":"2021","unstructured":"McMahon, M., Seto, R. & Skaggs, B. J. Cardiovascular disease in systemic lupus erythematosus. Rheumatol. Immunol. Res. 2, 157\u2013172 (2021).","journal-title":"Rheumatol. Immunol. Res."},{"key":"2168_CR363","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/CRD.0000000000000383","volume":"29","author":"CA Ballarano","year":"2021","unstructured":"Ballarano, C. A. & Frishman, W. H. Cardiovascular disease in patients with systemic lupus erythematosus: potential for improved primary prevention with statins. Cardiol. Rev. 29, 323\u2013327 (2021).","journal-title":"Cardiol. Rev."},{"key":"2168_CR364","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/rheumatology\/keg436","volume":"43","author":"J Wajed","year":"2004","unstructured":"Wajed, J., Ahmad, Y., Durrington, P. N. & Bruce, I. N. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatol. (Oxf.) 43, 7\u201312 (2004).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR365","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1177\/0961203317722847","volume":"26","author":"S Fasano","year":"2017","unstructured":"Fasano, S. et al. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus 26, 1463\u20131472 (2017).","journal-title":"Lupus"},{"key":"2168_CR366","first-page":"179","volume":"34","author":"J Miner","year":"2007","unstructured":"Miner, J. & Hoffhines, A. The discovery of aspirin\u2019s antithrombotic effects. Tex. Heart Inst. J. 34, 179\u2013186 (2007).","journal-title":"Tex. Heart Inst. J."},{"key":"2168_CR367","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000077340","volume":"17","author":"DW Dippel","year":"2004","unstructured":"Dippel, D. W. et al. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc. Dis. 17, 296\u2013302 (2004).","journal-title":"Cerebrovasc. Dis."},{"key":"2168_CR368","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/phar.1127","volume":"32","author":"CW Nemerovski","year":"2012","unstructured":"Nemerovski, C. W., Salinitri, F. D., Morbitzer, K. A. & Moser, L. R. Aspirin for primary prevention of cardiovascular disease events. Pharmacotherapy 32, 1020\u20131035 (2012).","journal-title":"Pharmacotherapy"},{"key":"2168_CR369","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00005792-199209000-00004","volume":"71","author":"M Petri","year":"1992","unstructured":"Petri, M., Spence, D., Bone, L. R. & Hochberg, M. C. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Med. (Baltim.) 71, 291\u2013302 (1992).","journal-title":"Med. (Baltim.)"},{"key":"2168_CR370","first-page":"813","volume":"94","author":"MH Liang","year":"2002","unstructured":"Liang, M. H., Mandl, L. A., Costenbader, K., Fox, E. & Karlson, E. Atherosclerotic vascular disease in systemic lupus erythematosus. J. Natl Med. Assoc. 94, 813\u2013819 (2002).","journal-title":"J. Natl Med. Assoc."},{"key":"2168_CR371","first-page":"170","volume":"9","author":"M Petri","year":"2000","unstructured":"Petri, M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins. Lupus Cohort. Lupus 9, 170\u2013175 (2000).","journal-title":"Lupus Cohort. Lupus"},{"key":"2168_CR372","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D","volume":"42","author":"S Manzi","year":"1999","unstructured":"Manzi, S. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42, 51\u201360 (1999).","journal-title":"Arthritis Rheum."},{"key":"2168_CR373","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1161\/hc4101.097518","volume":"104","author":"E Svenungsson","year":"2001","unstructured":"Svenungsson, E. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887\u20131893 (2001).","journal-title":"Circulation"},{"key":"2168_CR374","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3899\/jrheum.090306","volume":"37","author":"S Haque","year":"2010","unstructured":"Haque, S. et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J. Rheumatol. 37, 322\u2013329 (2010).","journal-title":"J. Rheumatol."},{"key":"2168_CR375","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/ar3473","volume":"13","author":"M Nikpour","year":"2011","unstructured":"Nikpour, M., Urowitz, M. B., Ibanez, D., Harvey, P. J. & Gladman, D. D. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res. Ther. 13, R156 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"2168_CR376","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/art.24677","volume":"60","author":"M McMahon","year":"2009","unstructured":"McMahon, M. et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 60, 2428\u20132437 (2009).","journal-title":"Arthritis Rheum."},{"key":"2168_CR377","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/1756-185X.13588","volume":"22","author":"JY Jung","year":"2019","unstructured":"Jung, J. Y., Kim, H. A., Lee, H. Y. & Suh, C. H. Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4 year follow-up study. Int. J. Rheum. Dis. 22, 1410\u20131418 (2019).","journal-title":"Int. J. Rheum. Dis."},{"key":"2168_CR378","doi-asserted-by":"publisher","first-page":"e000362","DOI":"10.1136\/lupus-2019-000362","volume":"7","author":"S Ajeganova","year":"2020","unstructured":"Ajeganova, S., Gustafsson, T., Lindberg, L., Hafstrom, I. & Frostegard, J. Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients. Lupus Sci. Med. 7, e000362 (2020).","journal-title":"Lupus Sci. Med."},{"key":"2168_CR379","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/ard.62.11.1071","volume":"62","author":"A Doria","year":"2003","unstructured":"Doria, A. et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62, 1071\u20131077 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR380","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/0961203311425524","volume":"21","author":"C Bengtsson","year":"2012","unstructured":"Bengtsson, C., Ohman, M. L., Nived, O. & Rantapaa Dahlqvist, S. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 21, 452\u2013459 (2012).","journal-title":"Lupus"},{"key":"2168_CR381","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/0961203307081113","volume":"16","author":"MB Urowitz","year":"2007","unstructured":"Urowitz, M. B. et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 16, 731\u2013735 (2007).","journal-title":"Lupus"},{"key":"2168_CR382","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/rheumatology\/kep102","volume":"48","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel, G. J. et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatol. (Oxf.) 48, 817\u2013822 (2009).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR383","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1136\/annrheumdis-2019-215896","volume":"79","author":"G Orsolini","year":"2020","unstructured":"Orsolini, G. et al. Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. Ann. Rheum. Dis. 79, e150 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR384","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0961203317711012","volume":"27","author":"DD Gladman","year":"2018","unstructured":"Gladman, D. D., Dhillon, N., Su, J. & Urowitz, M. B. Osteonecrosis in SLE: Prevalence, patterns, outcomes and predictors. Lupus 27, 76\u201381 (2018).","journal-title":"Lupus"},{"key":"2168_CR385","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1385\/CRIAI:25:1:13","volume":"25","author":"M Abu-Shakra","year":"2003","unstructured":"Abu-Shakra, M., Buskila, D. & Shoenfeld, Y. Osteonecrosis in patients with SLE. Clin. Rev. Allergy Immunol. 25, 13\u201324 (2003).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2168_CR386","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MEG.0000000000001312","volume":"31","author":"SW Lai","year":"2019","unstructured":"Lai, S. W., Lin, C. L. & Liao, K. F. Proton pump inhibitors therapy and the risk of major osteoporotic nonhip fractures in older adults in Taiwan. Eur. J. Gastroenterol. Hepatol. 31, 272\u2013273 (2019).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"2168_CR387","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3904\/kjim.2018.378","volume":"36","author":"CS Kim","year":"2021","unstructured":"Kim, C. S. et al. Incidence and risk factors for osteoporotic fractures in patients with systemic lupus erythematosus versus matched controls. Korean J. Intern. Med. 36, 154\u2013163 (2021).","journal-title":"Korean J. Intern. Med."},{"key":"2168_CR388","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/art.40818","volume":"71","author":"SK Tedeschi","year":"2019","unstructured":"Tedeschi, S. K., Kim, S. C., Guan, H., Grossman, J. M. & Costenbader, K. H. Comparative fracture risks among United States medicaid enrollees with and those without systemic lupus erythematosus. Arthritis Rheumatol. 71, 1141\u20131146 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR389","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/rheumatology\/ker277","volume":"50","author":"T Shigemura","year":"2011","unstructured":"Shigemura, T. et al. Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatol. (Oxf.) 50, 2023\u20132028 (2011).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR390","doi-asserted-by":"publisher","first-page":"102992","DOI":"10.1016\/j.autrev.2021.102992","volume":"21","author":"Y Zheng","year":"2022","unstructured":"Zheng, Y., Zheng, Z., Zhang, K. & Zhu, P. Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management. Autoimmun. Rev. 21, 102992 (2022).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR391","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41368-020-00093-2","volume":"12","author":"L He","year":"2020","unstructured":"He, L., Sun, X., Liu, Z., Qiu, Y. & Niu, Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int. J. Oral. Sci. 12, 30 (2020).","journal-title":"Int. J. Oral. Sci."},{"key":"2168_CR392","doi-asserted-by":"publisher","first-page":"601763","DOI":"10.1155\/2012\/601763","volume":"2012","author":"J Seamon","year":"2012","unstructured":"Seamon, J., Keller, T., Saleh, J. & Cui, Q. The pathogenesis of nontraumatic osteonecrosis. Arthritis 2012, 601763 (2012).","journal-title":"Arthritis"},{"key":"2168_CR393","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/096120339200100610","volume":"1","author":"L Massardo","year":"1992","unstructured":"Massardo, L. et al. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1, 401\u2013405 (1992).","journal-title":"Lupus"},{"key":"2168_CR394","doi-asserted-by":"crossref","unstructured":"Konarski, W. et al. Osteonecrosis related to steroid and alcohol use-an update on pathogenesis. Healthcare (Basel) 11, 1846 (2023).","DOI":"10.3390\/healthcare11131846"},{"key":"2168_CR395","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33965-8","volume":"13","author":"JB Kohler","year":"2023","unstructured":"Kohler, J. B. et al. Smoking induces increased apoptosis in osteoblasts: changes in bone matrix organic components. Sci. Rep. 13, 6938 (2023).","journal-title":"Sci. Rep."},{"key":"2168_CR396","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","volume":"15","author":"M Gatto","year":"2019","unstructured":"Gatto, M., Zen, M., Iaccarino, L. & Doria, A. New therapeutic strategies in systemic lupus erythematosus management. Nat. Rev. Rheumatol. 15, 30\u201348 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR397","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1002\/art.27679","volume":"62","author":"S Duran-Barragan","year":"2010","unstructured":"Duran-Barragan, S., Sandoval-Garcia, L. & Navarrete-Lorenzon, M. Additive risk factors resulting in severe osteonecrosis in systemic lupus erythematosus. Arthritis Rheum. 62, 3276 (2010).","journal-title":"Arthritis Rheum."},{"key":"2168_CR398","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/rheumatology\/key365","volume":"58","author":"R Hisada","year":"2019","unstructured":"Hisada, R. et al. Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. Rheumatol. (Oxf.) 58, 645\u2013649 (2019).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR399","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/0961203307076771","volume":"16","author":"SC Fialho","year":"2007","unstructured":"Fialho, S. C. et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16, 239\u2013244 (2007).","journal-title":"Lupus"},{"key":"2168_CR400","first-page":"761","volume":"28","author":"DD Gladman","year":"2001","unstructured":"Gladman, D. D., Urowitz, M. B., Chaudhry-Ahluwalia, V., Hallet, D. C. & Cook, R. J. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J. Rheumatol. 28, 761\u2013765 (2001).","journal-title":"J. Rheumatol."},{"key":"2168_CR401","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/acr.24541","volume":"74","author":"R Kallas","year":"2022","unstructured":"Kallas, R., Li, J. & Petri, M. Predictors of osteonecrosis in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res. (Hoboken) 74, 1122\u20131132 (2022).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR402","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/1744666X.2021.1925109","volume":"17","author":"W Qijiao","year":"2021","unstructured":"Qijiao, W. et al. Antiphospholipid antibodies and osteonecrosis in systemic lupus erythematosus: a meta-analysis. Expert Rev. Clin. Immunol. 17, 923\u2013932 (2021).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2168_CR403","first-page":"9208035","volume":"2016","author":"TH Kim","year":"2016","unstructured":"Kim, T. H., Bae, S. C., Lee, S. H., Kim, S. Y. & Baek, S. H. Association of complement receptor 2 gene polymorphisms with susceptibility to osteonecrosis of the femoral head in systemic lupus erythematosus. Biomed. Res. Int. 2016, 9208035 (2016).","journal-title":"Biomed. Res. Int."},{"key":"2168_CR404","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.12998\/wjcc.v8.i12.2530","volume":"8","author":"HS Sun","year":"2020","unstructured":"Sun, H. S. et al. Gene testing for osteonecrosis of the femoral head in systemic lupus erythematosus using targeted next-generation sequencing: A pilot study. World J. Clin. Cases 8, 2530\u20132541 (2020).","journal-title":"World J. Clin. Cases"},{"key":"2168_CR405","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molimm.2012.07.002","volume":"53","author":"R Asokan","year":"2013","unstructured":"Asokan, R., Banda, N. K., Szakonyi, G., Chen, X. S. & Holers, V. M. Human complement receptor 2 (CR2\/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol. Immunol. 53, 99\u2013110 (2013).","journal-title":"Mol. Immunol."},{"key":"2168_CR406","doi-asserted-by":"publisher","first-page":"303","DOI":"10.5414\/CP201972","volume":"52","author":"MS Joy","year":"2014","unstructured":"Joy, M. S. et al. A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int. J. Clin. Pharmacol. Ther. 52, 303\u2013313 (2014).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"2168_CR407","doi-asserted-by":"publisher","first-page":"e6049","DOI":"10.1097\/MD.0000000000006049","volume":"96","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Association of ABCB1 C3435T polymorphism with the susceptibility to osteonecrosis of the femoral head: A meta-analysis. Med. (Baltim.) 96, e6049 (2017).","journal-title":"Med. (Baltim.)"},{"key":"2168_CR408","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1590\/S0100-879X2008000900005","volume":"41","author":"TP Gonzalez","year":"2008","unstructured":"Gonzalez, T. P. et al. ABCB1 C1236T, G2677T\/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz. J. Med. Biol. Res. 41, 769\u2013772 (2008).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"2168_CR409","doi-asserted-by":"crossref","unstructured":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 42, 599-608 (1999).","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"2168_CR410","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.40591","volume":"71","author":"JG Hanly","year":"2019","unstructured":"Hanly, J. G., Kozora, E., Beyea, S. D. & Birnbaum, J. Review: nervous system disease in systemic lupus erythematosus: current status and future directions. Arthritis Rheumatol. 71, 33\u201342 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR411","first-page":"985","volume":"30","author":"G Sanna","year":"2003","unstructured":"Sanna, G. et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30, 985\u2013992 (2003).","journal-title":"J. Rheumatol."},{"key":"2168_CR412","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1212\/WNL.58.8.1214","volume":"58","author":"RL Brey","year":"2002","unstructured":"Brey, R. L. et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58, 1214\u20131220 (2002).","journal-title":"Neurology"},{"key":"2168_CR413","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0961203307085671","volume":"17","author":"HQ Zhou","year":"2008","unstructured":"Zhou, H. Q. et al. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus 17, 93\u201399 (2008).","journal-title":"Lupus"},{"key":"2168_CR414","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.semarthrit.2018.02.007","volume":"48","author":"HA Rayes","year":"2018","unstructured":"Rayes, H. A. et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin. Arthritis Rheum. 48, 240\u2013255 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"2168_CR415","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.57.3.496","volume":"57","author":"H Ainiala","year":"2001","unstructured":"Ainiala, H., Loukkola, J., Peltola, J., Korpela, M. & Hietaharju, A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57, 496\u2013500 (2001).","journal-title":"Neurology"},{"key":"2168_CR416","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/rheumatology\/kex018","volume":"56","author":"SH Tay","year":"2017","unstructured":"Tay, S. H. & Mak, A. Diagnosing and attributing neuropsychiatric events to systemic lupus erythematosus: time to untie the Gordian knot? Rheumatol. (Oxf.) 56, i14\u2013i23 (2017).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR417","doi-asserted-by":"publisher","first-page":"e0196103","DOI":"10.1371\/journal.pone.0196103","volume":"13","author":"F Ceccarelli","year":"2018","unstructured":"Ceccarelli, F. et al. Cognitive dysfunction improves in systemic lupus erythematosus: Results of a 10 years prospective study. PLoS One 13, e0196103 (2018).","journal-title":"PLoS One"},{"key":"2168_CR418","doi-asserted-by":"publisher","first-page":"e33824","DOI":"10.1371\/journal.pone.0033824","volume":"7","author":"F Conti","year":"2012","unstructured":"Conti, F. et al. Neurocognitive dysfunction in systemic lupus erythematosus: Association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 7, e33824 (2012).","journal-title":"PLoS One"},{"issue":"Suppl 10","key":"2168_CR419","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/acr.24364","volume":"72","author":"K Yuen","year":"2020","unstructured":"Yuen, K., Bingham, K., Tayer-Shifman, O. E. & Touma, Z. Measures of cognition in rheumatic diseases. Arthritis Care Res. (Hoboken) 72(Suppl 10), 660\u2013675 (2020).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR420","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/art.23090","volume":"57","author":"P Panopalis","year":"2007","unstructured":"Panopalis, P. et al. Impact of memory impairment on employment status in persons with systemic lupus erythematosus. Arthritis Rheum. 57, 1453\u20131460 (2007).","journal-title":"Arthritis Rheum."},{"key":"2168_CR421","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1002\/art.23991","volume":"58","author":"E Kozora","year":"2008","unstructured":"Kozora, E., Hanly, J. G., Lapteva, L. & Filley, C. M. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum. 58, 3286\u20133298 (2008).","journal-title":"Arthritis Rheum."},{"key":"2168_CR422","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40744-021-00312-0","volume":"8","author":"D Seet","year":"2021","unstructured":"Seet, D., Allameen, N. A., Tay, S. H., Cho, J. & Mak, A. Cognitive dysfunction in systemic lupus erythematosus: immunopathology, clinical manifestations, neuroimaging and management. Rheumatol. Ther. 8, 651\u2013679 (2021).","journal-title":"Rheumatol. Ther."},{"key":"2168_CR423","doi-asserted-by":"crossref","unstructured":"Ewees, M. G., El-Mahdy, M. A., Hannawi, Y. & Zweier, J. L. Tobacco cigarette smoking induces cerebrovascular dysfunction followed by oxidative neuronal injury with the onset of cognitive impairment. J. Cereb. Blood Flow Metab., 271678\u00d7241270415 (2024).","DOI":"10.1177\/0271678X241270415"},{"key":"2168_CR424","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yhbeh.2018.01.002","volume":"99","author":"J Balthazart","year":"2018","unstructured":"Balthazart, J., Choleris, E. & Remage-Healey, L. Steroids and the brain: 50years of research, conceptual shifts and the ascent of non-classical and membrane-initiated actions. Horm. Behav. 99, 1\u20138 (2018).","journal-title":"Horm. Behav."},{"key":"2168_CR425","first-page":"CD005593","volume":"2006","author":"J Birks","year":"2006","unstructured":"Birks, J. Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst. Rev. 2006, CD005593 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2168_CR426","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1177\/0961203316642313","volume":"25","author":"E Montero-Lopez","year":"2016","unstructured":"Montero-Lopez, E. et al. The effects of corticosteroids on cognitive flexibility and decision-making in women with lupus. Lupus 25, 1470\u20131478 (2016).","journal-title":"Lupus"},{"key":"2168_CR427","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/rheumatology\/keaa002","volume":"59","author":"R Teo","year":"2020","unstructured":"Teo, R., Dhanasekaran, P., Tay, S. H. & Mak, A. Mathematical processing is affected by daily but not cumulative glucocorticoid dose in patients with systemic lupus erythematosus. Rheumatol. (Oxf.) 59, 2534\u20132543 (2020).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR428","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1440-1819.2009.02005.x","volume":"63","author":"P Fietta","year":"2009","unstructured":"Fietta, P., Fietta, P. & Delsante, G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin. Neurosci. 63, 613\u2013622 (2009).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"2168_CR429","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2003.09.010","volume":"55","author":"ES Brown","year":"2004","unstructured":"Brown, E. S. et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol. Psychiatry 55, 538\u2013545 (2004).","journal-title":"Biol. Psychiatry"},{"key":"2168_CR430","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1212\/01.WNL.0000149640.78684.EA","volume":"64","author":"EY McLaurin","year":"2005","unstructured":"McLaurin, E. Y., Holliday, S. L., Williams, P. & Brey, R. L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64, 297\u2013303 (2005).","journal-title":"Neurology"},{"key":"2168_CR431","doi-asserted-by":"publisher","first-page":"e0177332","DOI":"10.1371\/journal.pone.0177332","volume":"12","author":"B Niego","year":"2017","unstructured":"Niego, B. et al. Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin. PLoS One 12, e0177332 (2017).","journal-title":"PLoS One"},{"key":"2168_CR432","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/ehac179","volume":"43","author":"S Parish","year":"2022","unstructured":"Parish, S. et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur. Heart J. 43, 2010\u20132019 (2022).","journal-title":"Eur. Heart J."},{"key":"2168_CR433","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/bmj.39204.473252.80","volume":"334","author":"LJ Whalley","year":"2007","unstructured":"Whalley, L. J. & Mowat, D. H. Aspirin and cognitive function. BMJ 334, 961\u2013962 (2007).","journal-title":"BMJ"},{"key":"2168_CR434","doi-asserted-by":"publisher","first-page":"578071","DOI":"10.3389\/fnagi.2020.578071","volume":"12","author":"H Li","year":"2020","unstructured":"Li, H., Li, W., Zhang, X., Ma, X. C. & Zhang, R. W. Aspirin use on incident dementia and mild cognitive decline: a systematic review and meta-analysis. Front Aging Neurosci. 12, 578071 (2020).","journal-title":"Front Aging Neurosci."},{"key":"2168_CR435","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1532-5415.2010.02827.x","volume":"58","author":"OP Almeida","year":"2010","unstructured":"Almeida, O. P., Alfonso, H., Jamrozik, K., Hankey, G. J. & Flicker, L. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J. Am. Geriatr. Soc. 58, 990\u2013992 (2010).","journal-title":"J. Am. Geriatr. Soc."},{"key":"2168_CR436","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.brainres.2010.11.067","volume":"1371","author":"T Kurata","year":"2011","unstructured":"Kurata, T. et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371, 161\u2013170 (2011).","journal-title":"Brain Res"},{"key":"2168_CR437","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1474-4422(04)00767-7","volume":"3","author":"L Fratiglioni","year":"2004","unstructured":"Fratiglioni, L., Paillard-Borg, S. & Winblad, B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 3, 343\u2013353 (2004).","journal-title":"Lancet Neurol."},{"key":"2168_CR438","first-page":"661","volume":"9","author":"A Carvalho","year":"2014","unstructured":"Carvalho, A., Rea, I. M., Parimon, T. & Cusack, B. J. Physical activity and cognitive function in individuals over 60 years of age: a systematic review. Clin. Interv. Aging 9, 661\u2013682 (2014).","journal-title":"Clin. Interv. Aging"},{"key":"2168_CR439","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1152\/advan.00101.2014","volume":"39","author":"JNExercise Barnes","year":"2015","unstructured":"Barnes, J. N. Exercise cognitive function, and aging. Adv. Physiol. Educ. 39, 55\u201362 (2015).","journal-title":"Adv. Physiol. Educ."},{"key":"2168_CR440","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0961203314551810","volume":"24","author":"E Kozora","year":"2015","unstructured":"Kozora, E. et al. Cardiopulmonary correlates of cognition in systemic lupus erythematosus. Lupus 24, 164\u2013173 (2015).","journal-title":"Lupus"},{"key":"2168_CR441","first-page":"429","volume":"55","author":"N Agarwal","year":"2016","unstructured":"Agarwal, N. & Kumar, V. Burden of lupus on work: Issues in the employment of individuals with lupus. Work 55, 429\u2013439 (2016).","journal-title":"Work"},{"key":"2168_CR442","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/acr.23593","volume":"71","author":"TA Lillis","year":"2019","unstructured":"Lillis, T. A. et al. Sleep disturbance and depression symptoms mediate relationship between pain and cognitive dysfunction in lupus. Arthritis Care Res. (Hoboken) 71, 406\u2013412 (2019).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR443","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/reum.2018.74750","volume":"56","author":"M Olesinska","year":"2018","unstructured":"Olesinska, M. & Saletra, A. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia 56, 45\u201354 (2018).","journal-title":"Reumatologia"},{"key":"2168_CR444","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0022-510X(00)00492-5","volume":"184","author":"R Monastero","year":"2001","unstructured":"Monastero, R. et al. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J. Neurol. Sci. 184, 33\u201339 (2001).","journal-title":"J. Neurol. Sci."},{"key":"2168_CR445","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/art.1780370907","volume":"37","author":"SD Denburg","year":"1994","unstructured":"Denburg, S. D., Carbotte, R. M. & Denburg, J. A. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 37, 1311\u20131320 (1994).","journal-title":"Arthritis Rheum."},{"key":"2168_CR446","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1177\/096120330101001103","volume":"10","author":"GR Hughes","year":"2001","unstructured":"Hughes, G. R., Cuadrado, M. J., Khamashta, M. A. & Sanna, G. Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome. Lupus 10, 778 (2001).","journal-title":"Lupus"},{"key":"2168_CR447","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.semarthrit.2011.02.005","volume":"41","author":"M Petri","year":"2011","unstructured":"Petri, M., Naqibuddin, M., Sampedro, M., Omdal, R. & Carson, K. A. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin. Arthritis Rheum. 41, 194\u2013202 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"2168_CR448","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jama.2020.0435","volume":"323","author":"Force, U. S. P. S. T.","year":"2020","unstructured":"Force, U. S. P. S. T. et al. Screening for cognitive impairment in older adults: US preventive services task force recommendation statement. JAMA 323, 757\u2013763 (2020).","journal-title":"JAMA"},{"key":"2168_CR449","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0898264315569454","volume":"27","author":"J Chodosh","year":"2015","unstructured":"Chodosh, J. et al. Dementia care management in an underserved community: The comparative effectiveness of two different approaches. J. Aging Health 27, 864\u2013893 (2015).","journal-title":"J. Aging Health"},{"key":"2168_CR450","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.molimm.2014.06.039","volume":"61","author":"A Jacob","year":"2014","unstructured":"Jacob, A. & Alexander, J. J. Complement and blood-brain barrier integrity. Mol. Immunol. 61, 149\u2013152 (2014).","journal-title":"Mol. Immunol."},{"key":"2168_CR451","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/eji.200636638","volume":"37","author":"JJ Alexander","year":"2007","unstructured":"Alexander, J. J. et al. Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur. J. Immunol. 37, 1691\u20131701 (2007).","journal-title":"Eur. J. Immunol."},{"key":"2168_CR452","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/cpt.3216","volume":"115","author":"L Klopp-Schulze","year":"2024","unstructured":"Klopp-Schulze, L. et al. Asia-inclusive global development of enpatoran: results of an ethno-bridging study, intrinsic\/extrinsic factor assessments and disease trajectory modeling to inform design of a phase II multiregional clinical trial. Clin. Pharmacol. Ther. 115, 1346\u20131357 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2168_CR453","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/annrheumdis-2022-eular.4386","volume":"81","author":"EF Morand","year":"2022","unstructured":"Morand, E. F. et al. AB0444 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and\/or CLE (WILLOW). Ann. Rheum. Dis. 81, 1350\u20131351 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR454","doi-asserted-by":"publisher","first-page":"175962","DOI":"10.1016\/j.ejphar.2023.175962","volume":"957","author":"ST Ishizaka","year":"2023","unstructured":"Ishizaka, S. T. et al. A novel Toll-like receptor 7\/8-specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus. Eur. J. Pharmacol. 957, 175962 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"2168_CR455","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","volume":"8","author":"DJ Wallace","year":"2012","unstructured":"Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H. & Venuturupalli, S. R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8, 522\u2013533 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR456","doi-asserted-by":"publisher","first-page":"e008686","DOI":"10.1161\/CIRCEP.120.008686","volume":"13","author":"DM Friedman","year":"2020","unstructured":"Friedman, D. M. et al. Electrocardiographic QT intervals in infants exposed to hydroxychloroquine throughout gestation. Circ. Arrhythm. Electrophysiol. 13, e008686 (2020).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"2168_CR457","doi-asserted-by":"publisher","first-page":"1759720\u00d72110730","DOI":"10.1177\/1759720X211073001","volume":"14","author":"A Dima","year":"2022","unstructured":"Dima, A., Jurcut, C., Chasset, F., Felten, R. & Arnaud, L. Hydroxychloroquine in systemic lupus erythematosus: Overview of current knowledge. Ther. Adv. Musculoskelet. Dis. 14, 1759720\u00d7211073001 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"2168_CR458","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00431-023-04837-0","volume":"182","author":"FS Gheet","year":"2023","unstructured":"Gheet, F. S., Dawoud, H. E., El-Shahaby, W. A., Elrifaey, S. M. & Abdelnabi, H. H. Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur. J. Pediatr. 182, 1685\u20131695 (2023).","journal-title":"Eur. J. Pediatr."},{"key":"2168_CR459","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1056\/NEJM195407082510202","volume":"251","author":"MJ Tye","year":"1954","unstructured":"Tye, M. J., Schiff, B. L., Collins, S. F., Baler, G. R. & Appel, B. Chronic discoid lupus erythematosus: treatment with daraprim and chloroquine diphosphate (aralen). N. Engl. J. Med. 251, 52\u201355 (1954).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR460","first-page":"169","volume":"22","author":"L Lu","year":"2002","unstructured":"Lu, L. Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis. Zhongguo Zhong Xi Yi Jie He Za Zhi 22, 169\u2013171 (2002).","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"2168_CR461","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(51)91643-1","volume":"2","author":"F Page","year":"1951","unstructured":"Page, F. Treatment of lupus erythematosus with mepacrine. Lancet 2, 755\u2013758 (1951).","journal-title":"Lancet"},{"key":"2168_CR462","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794\u20134804 (2011).","journal-title":"J. Immunol."},{"key":"2168_CR463","doi-asserted-by":"publisher","first-page":"e12476","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk, E. L., Reggiori, F. & Mauthe, M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol. Med. 12, e12476 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2168_CR464","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428194.2021.1975192","volume":"63","author":"NR Wilson","year":"2022","unstructured":"Wilson, N. R. et al. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk. Lymphoma 63, 19\u201330 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"2168_CR465","doi-asserted-by":"crossref","unstructured":"Ngo, C., Garrec, C., Tomasello, E. & Dalod, M. The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond. Cell Mol. Immunol. 21, 1008\u20131035 (2024).","DOI":"10.1038\/s41423-024-01167-5"},{"key":"2168_CR466","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1172\/JCI124466","volume":"129","author":"R Furie","year":"2019","unstructured":"Furie, R. et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J. Clin. Invest. 129, 1359\u20131371 (2019).","journal-title":"J. Clin. Invest."},{"key":"2168_CR467","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","volume":"387","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N. Engl. J. Med. 387, 894\u2013904 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR468","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth, V. P. et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N. Engl. J. Med. 387, 321\u2013331 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR469","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496\u2013506 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR470","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian, K. C. et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 75, 253\u2013265 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR471","unstructured":"astrazeneca.com. Saphnelo demonstrates higher rates of remission in patients with systemic lupus erythematosus compared to standard therapy alone over 4-year period. (2024)."},{"key":"2168_CR472","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks, E. D. Anifrolumab: First approval. Drugs 81, 1795\u20131802 (2021).","journal-title":"Drugs"},{"key":"2168_CR473","doi-asserted-by":"crossref","unstructured":"Martin-Torregrosa, D., Mansilla-Polo, M. & Morgado-Carrasco, D. Use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses. Actas Dermosifiliogr (2024).","DOI":"10.1016\/j.ad.2024.10.008"},{"key":"2168_CR474","unstructured":"astrazeneca.com.cn. The first-in-class drug Saphnelo for the treatment of systemic lupus erythematosus has officially been introduced in the Guangdong-Hong Kong-Macao Greater Bay Area., https:\/\/www.astrazeneca.com.cn\/zh\/media\/press-releases\/2024\/10-21-01.html#! (2024)."},{"key":"2168_CR475","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/rheumatology\/kew262","volume":"55","author":"J Ducreux","year":"2016","unstructured":"Ducreux, J. et al. Interferon \u03b1 kinoid induces neutralizing anti-interferon \u03b1 antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon \u03b1 kinoid phase I\/II study. Rheumatol. (Oxf.) 55, 1901\u20131905 (2016).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR476","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta, M. et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 1909\u20131916 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR477","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","volume":"75","author":"KC Kalunian","year":"2016","unstructured":"Kalunian, K. C. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75, 196\u2013202 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR478","doi-asserted-by":"crossref","unstructured":"Baker, M. et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open 6, e001490 (2020).","DOI":"10.1136\/rmdopen-2020-001490"},{"key":"2168_CR479","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","volume":"61","author":"VP Werth","year":"2022","unstructured":"Werth, V. P. et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatol. (Oxf.) 61, 2413\u20132423 (2022).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR480","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/7445","volume":"5","author":"DA Frank","year":"1999","unstructured":"Frank, D. A., Mahajan, S. & Ritz, J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 5, 444\u2013447 (1999).","journal-title":"Nat. Med."},{"key":"2168_CR481","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/rheumatology\/kem001","volume":"46","author":"GG Illei","year":"2007","unstructured":"Illei, G. G. et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatol. (Oxf.) 46, 952\u2013956 (2007).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR482","unstructured":"ClinicalTrials.gov. Efficacy and safety of artesunate plus standard of care in active lupus nephritis (AURORA), https:\/\/clinicaltrials.gov\/study\/NCT03214731 (2019)."},{"key":"2168_CR483","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/rheumatology\/key064","volume":"58","author":"PL Carreira","year":"2019","unstructured":"Carreira, P. L. & Isenberg, D. A. Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus. Rheumatol. (Oxf.) 58, 382\u2013387 (2019).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR484","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/art.40470","volume":"70","author":"M Wilhelm","year":"2018","unstructured":"Wilhelm, M. et al. Lupus regulator peptide P140 represses B cell differentiation by reducing HLA class II molecule overexpression. Arthritis Rheumatol. 70, 1077\u20131088 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR485","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1002\/art.24027","volume":"58","author":"S Muller","year":"2008","unstructured":"Muller, S. et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 58, 3873\u20133883 (2008).","journal-title":"Arthritis Rheum."},{"key":"2168_CR486","unstructured":"ClinicalTrials.gov. A 52-Week, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with systemic lupus erythematosus (LUPUZOR), https:\/\/clinicaltrials.gov\/study\/NCT02504645 (2019)."},{"key":"2168_CR487","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.autrev.2023.103404","volume":"22","author":"M Xipell","year":"2023","unstructured":"Xipell, M. et al. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmun. Rev. 22, 103404 (2023).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR488","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/gut.39.1.63","volume":"39","author":"EC Van Os","year":"1996","unstructured":"Van Os, E. C. et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 39, 63\u201368 (1996).","journal-title":"Gut"},{"key":"2168_CR489","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","volume":"17","author":"JT Ransom","year":"1995","unstructured":"Ransom, J. T. Mechanism of action of mycophenolate mofetil. Ther. Drug Monit. 17, 681\u2013684 (1995).","journal-title":"Ther. Drug Monit."},{"key":"2168_CR490","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3109\/s10165-007-0567-x","volume":"17","author":"T Kuroda","year":"2007","unstructured":"Kuroda, T. et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod. Rheumatol. 17, 206\u2013212 (2007).","journal-title":"Mod. Rheumatol."},{"key":"2168_CR491","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11255-007-9325-4","volume":"41","author":"A Sabry","year":"2009","unstructured":"Sabry, A. et al. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. Int. Urol. Nephrol. 41, 153\u2013161 (2009).","journal-title":"Int. Urol. Nephrol."},{"key":"2168_CR492","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2022-222486","volume":"81","author":"Q Fu","year":"2022","unstructured":"Fu, Q. et al. Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. Ann. Rheum. Dis. 81, 1549\u20131555 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR493","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1681\/ASN.2008060665","volume":"20","author":"HA Austin 3rd","year":"2009","unstructured":"Austin, H. A. 3rd, Illei, G. G., Braun, M. J. & Balow, J. E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901\u2013911 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2168_CR494","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","volume":"38","author":"M Zhang","year":"2019","unstructured":"Zhang, M. et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin. Rheumatol. 38, 859\u2013867 (2019).","journal-title":"Clin. Rheumatol."},{"key":"2168_CR495","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.22505","volume":"56","author":"I Gunnarsson","year":"2007","unstructured":"Gunnarsson, I. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263\u20131272 (2007).","journal-title":"Arthritis Rheum."},{"key":"2168_CR496","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1177\/0961203310371155","volume":"19","author":"J Zavada","year":"2010","unstructured":"Zavada, J. et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19, 1281\u20131289 (2010).","journal-title":"Lupus"},{"key":"2168_CR497","doi-asserted-by":"publisher","first-page":"1298650","DOI":"10.3389\/fimmu.2023.1298650","volume":"14","author":"L Huang","year":"2023","unstructured":"Huang, L. et al. Combination treatment with telitacicept, cyclophosphamide and glucocorticoids for severe Granulomatous polyangiitis: a case report and literature review. Front. Immunol. 14, 1298650 (2023).","journal-title":"Front. Immunol."},{"key":"2168_CR498","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","volume":"75","author":"CC Mok","year":"2016","unstructured":"Mok, C. C. et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann. Rheum. Dis. 75, 30\u201336 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR499","doi-asserted-by":"publisher","first-page":"717","DOI":"10.4103\/1319-2442.185233","volume":"27","author":"BG Kaballo","year":"2016","unstructured":"Kaballo, B. G., Ahmed, A. E., Nur, M. M., Khalid, I. O. & Abu-Aisha, H. Mycophenolate mofetil versus azathioprine for maintenance treatment of lupus nephritis. Saudi J. Kidney Dis. Transpl. 27, 717\u2013725 (2016).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"2168_CR500","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","volume":"343","author":"TM Chan","year":"2000","unstructured":"Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343, 1156\u20131162 (2000).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR501","first-page":"2103","volume":"28","author":"S Buratti","year":"2001","unstructured":"Buratti, S., Szer, I. S., Spencer, C. H., Bartosh, S. & Reiff, A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J. Rheumatol. 28, 2103\u20132108 (2001).","journal-title":"J. Rheumatol."},{"key":"2168_CR502","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-007-0635-9","volume":"27","author":"H Tanaka","year":"2008","unstructured":"Tanaka, H., Tsugawa, K., Oki, E., Suzuki, K. & Ito, E. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin. Rheumatol. 27, 85\u201389 (2008).","journal-title":"Clin. Rheumatol."},{"key":"2168_CR503","first-page":"404","volume":"23","author":"JM Dayer","year":"2005","unstructured":"Dayer, J. M. & Cutolo, M. Is there a rationale to using leflunomide in early rheumatoid arthritis? Clin. Exp. Rheumatol. 23, 404\u2013412 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2168_CR504","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/ard.2005.044248","volume":"65","author":"LS Tam","year":"2006","unstructured":"Tam, L. S. et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann. Rheum. Dis. 65, 417\u2013418 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR505","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","volume":"81","author":"YA Heo","year":"2021","unstructured":"Heo, Y. A. Voclosporin: first approval. Drugs 81, 605\u2013610 (2021).","journal-title":"Drugs"},{"key":"2168_CR506","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann. Rheum. Dis. 83, 15\u201329 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR507","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","volume":"16","author":"JCA Broen","year":"2020","unstructured":"Broen, J. C. A. & van Laar, J. M. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat. Rev. Rheumatol. 16, 167\u2013178 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR508","doi-asserted-by":"publisher","first-page":"1331800","DOI":"10.3389\/fphar.2024.1331800","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang, M., Zhou, J., Niu, Q. & Wang, H. Mechanism of tacrolimus in the treatment of lupus nephritis. Front. Pharmacol. 15, 1331800 (2024).","journal-title":"Front. Pharmacol."},{"key":"2168_CR509","doi-asserted-by":"publisher","first-page":"c165","DOI":"10.1159\/000346149","volume":"121","author":"H Tanaka","year":"2012","unstructured":"Tanaka, H. et al. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron. Clin. Pract. 121, c165\u2013c173 (2012).","journal-title":"Nephron. Clin. Pract."},{"key":"2168_CR510","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","volume":"79","author":"CC Mok","year":"2020","unstructured":"Mok, C. C. et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann. Rheum. Dis. 79, 1070\u20131076 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR511","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/0961203317739131","volume":"27","author":"N Kamanamool","year":"2018","unstructured":"Kamanamool, N. et al. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial. Lupus 27, 647\u2013656 (2018).","journal-title":"Lupus"},{"key":"2168_CR512","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/acr.25007","volume":"75","author":"C Arriens","year":"2023","unstructured":"Arriens, C. et al. Update on the efficacy and safety profile of voclosporin: an integrated analysis of clinical trials in lupus nephritis. Arthritis Care Res. (Hoboken) 75, 1399\u20131408 (2023).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"2168_CR513","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2215\/CJN.0000000000000297","volume":"19","author":"H Menn-Josephy","year":"2024","unstructured":"Menn-Josephy, H., Hodge, L. S., Birardi, V. & Leher, H. Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria. Clin. J. Am. Soc. Nephrol. 19, 309\u2013318 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2168_CR514","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070\u20132080 (2021).","journal-title":"Lancet"},{"key":"2168_CR515","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena, A. et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 76, 59\u201367 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR516","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","volume":"95","author":"BH Rovin","year":"2019","unstructured":"Rovin, B. H. et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95, 219\u2013231 (2019).","journal-title":"Kidney Int"},{"key":"2168_CR517","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","volume":"219","author":"T Tang","year":"2021","unstructured":"Tang, T. et al. Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol. Ther. 219, 107709 (2021).","journal-title":"Pharmacol. Ther."},{"key":"2168_CR518","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/jcph.2188","volume":"63","author":"C Acharya","year":"2023","unstructured":"Acharya, C., Magnusson, M. O., Vajjah, P., Oliver, R. & Zamacona, M. Population pharmacokinetics and exposure-response for dapirolizumab pegol from a phase 2b trial in patients With systemic lupus erythematosus. J. Clin. Pharmacol. 63, 435\u2013444 (2023).","journal-title":"J. Clin. Pharmacol."},{"key":"2168_CR519","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie, R. A. et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatol. (Oxf.) 60, 5397\u20135407 (2021).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR520","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay, F. & Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491\u2013502 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2168_CR521","first-page":"197","volume":"30","author":"H Hsu","year":"2012","unstructured":"Hsu, H. et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin. Exp. Rheumatol. 30, 197\u2013201 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2168_CR522","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.40861","volume":"71","author":"DJ Wallace","year":"2019","unstructured":"Wallace, D. J. et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 71, 1125\u20131134 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR523","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","volume":"81","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population. Am. J. Kidney Dis. 81, 294\u2013306.e291 (2023).","journal-title":"Am. J. Kidney Dis."},{"key":"2168_CR524","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin, B. H. et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101, 403\u2013413 (2022).","journal-title":"Kidney Int"},{"key":"2168_CR525","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill, J. T. et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 883\u2013889 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR526","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie, R. A. et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann. Rheum. Dis. 74, 1667\u20131675 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR527","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg, D. A. et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 323\u2013331 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR528","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill, J. T. et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 332\u2013340 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR529","unstructured":"ClinicalTrials.gov. Clinical trials of ianalumab on lupus treatment, https:\/\/clinicaltrials.gov\/search?cond=lupus&term=Ianalumab (2024)."},{"key":"2168_CR530","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 70, 266\u2013276 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR531","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","volume":"74","author":"D Isenberg","year":"2015","unstructured":"Isenberg, D. et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74, 2006\u20132015 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR532","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/art.39809","volume":"69","author":"C Gordon","year":"2017","unstructured":"Gordon, C. et al. Post Hoc Analysis of the Phase II\/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL. Arthritis Rheumatol. 69, 122\u2013130 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR533","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Telitacicept: first approval. Drugs 81, 1671\u20131675 (2021).","journal-title":"Drugs"},{"key":"2168_CR534","first-page":"906","volume":"37","author":"M Zhang","year":"2019","unstructured":"Zhang, M. et al. Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin. Exp. Rheumatol. 37, 906\u2013914 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"2168_CR535","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cpt.2929","volume":"114","author":"L Abuqayyas","year":"2023","unstructured":"Abuqayyas, L. et al. Pharmacokinetics and Pharmacokinetic\/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials. Clin. Pharmacol. Ther. 114, 371\u2013380 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2168_CR536","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","volume":"38","author":"J Rip","year":"2018","unstructured":"Rip, J., Van Der Ploeg, E. K., Hendriks, R. W. & Corneth, O. B. J. The role of Bruton\u2019s tyrosine kinase in immune cell signaling and systemic autoimmunity. Crit. Rev. Immunol. 38, 17\u201362 (2018).","journal-title":"Crit. Rev. Immunol."},{"key":"2168_CR537","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3389\/fimmu.2017.01986","volume":"8","author":"AB Satterthwaite","year":"2017","unstructured":"Satterthwaite, A. B. Bruton\u2019s tyrosine kinase, a component of B cell signaling pathways, has multiple roles in the pathogenesis of lupus. Front. Immunol. 8, 1986 (2017).","journal-title":"Front. Immunol."},{"key":"2168_CR538","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/acs.jmedchem.9b00167","volume":"62","author":"SH Watterson","year":"2019","unstructured":"Watterson, S. H. et al. Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton\u2019s tyrosine kinase (BTK). J. Med. Chem. 62, 3228\u20133250 (2019).","journal-title":"J. Med. Chem."},{"key":"2168_CR539","unstructured":"ClinicalTrials.gov. Study to assess safety and effectiveness of branebrutinib treatment in participants with active systemic lupus erythematosus or primary Sj\u00f6gren\u2019s Syndrome, or branebrutinib treatment followed by open-label abatacept treatment in study participants with active rheumatoid arthritis, https:\/\/clinicaltrials.gov\/study\/NCT04186871 (2020)."},{"key":"2168_CR540","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 73, 1835\u20131846 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR541","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr2.11511","volume":"5","author":"DJ Wallace","year":"2023","unstructured":"Wallace, D. J. et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial. ACR Open Rheumatol. 5, 38\u201348 (2023).","journal-title":"ACR Open Rheumatol."},{"key":"2168_CR542","unstructured":"ClinicalTrials.gov. A study of ICP-022 in patients with systemic lupus erythematosus (SLE), https:\/\/clinicaltrials.gov\/study\/NCT04305197 (2020)."},{"key":"2168_CR543","unstructured":"ClinicalTrials.gov. Evaluate the efficacy and safety of orelabrutinib in adult patients with systemic lupus erythematosus, https:\/\/clinicaltrials.gov\/study\/NCT05688696 (2023)."},{"key":"2168_CR544","unstructured":"ClinicalTrials.govZanubrutinib in participants with Active proliferative lupus nephritis, https:\/\/clinicaltrials.gov\/study\/NCT04643470 (2020)."},{"key":"2168_CR545","unstructured":"ClinicalTrials.gov. Study of AC0058TA in patients with systemic lupus erythematosus (SLE), https:\/\/clinicaltrials.gov\/study\/NCT03878303 (2018)."},{"key":"2168_CR546","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.iy.09.040191.000525","volume":"9","author":"EA Clark","year":"1991","unstructured":"Clark, E. A. & Lane, P. J. Regulation of human B-cell activation and adhesion. Annu. Rev. Immunol. 9, 97\u2013127 (1991).","journal-title":"Annu. Rev. Immunol."},{"key":"2168_CR547","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","volume":"19","author":"RR Hardy","year":"2001","unstructured":"Hardy, R. R. & Hayakawa, K. B cell development pathways. Annu. Rev. Immunol. 19, 595\u2013621 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"2168_CR548","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill, J. T. et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: A double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 75, 2185\u20132194 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR549","doi-asserted-by":"crossref","unstructured":"Chung, J. B., Brudno, J. N., Borie, D. & Kochenderfer, J. N. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat. Rev. Immunol. 24, 830\u2013845 (2024).","DOI":"10.1038\/s41577-024-01035-3"},{"key":"2168_CR550","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531\u2013544 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2168_CR551","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"2168_CR552","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR553","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR554","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin, X. et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol. Immunol. 18, 1896\u20131903 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2168_CR555","doi-asserted-by":"crossref","unstructured":"Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. (2024).","DOI":"10.1136\/ard-2024-225785"},{"key":"2168_CR556","unstructured":"ClinicalTrials.gov. Descartes-08 for patients with systemic lupus erythematosus (SLE-001), https:\/\/clinicaltrials.gov\/study\/NCT06038474 (2024)."},{"key":"2168_CR557","unstructured":"ClinicalTrials.gov. A study of C-CAR168 in the treatment of autoimmune diseases refractory to standard therapy (CAR-AID), https:\/\/clinicaltrials.gov\/study\/NCT06249438 (2024)."},{"key":"2168_CR558","unstructured":"ClinicalTrials.gov. IMPT-514 in systemic lupus erythematosus, anca-associated vasculitis, and idiopathic inflammatory myopathy, https:\/\/clinicaltrials.gov\/study\/NCT06462144 (2024)."},{"key":"2168_CR559","unstructured":"ClinicalTrials.gov. A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE), https:\/\/clinicaltrials.gov\/study\/NCT06153095 (2024)."},{"key":"2168_CR560","unstructured":"ClinicalTrials.gov. JWCAR201 for the treatment of hematology malignancy and autoimmune diseases, https:\/\/clinicaltrials.gov\/study\/NCT06567080 (2024)."},{"key":"2168_CR561","unstructured":"ClinicalTrials.gov. Universal CAR-T cells (BRL-301) in refractory systemic lupus erythematosus, https:\/\/clinicaltrials.gov\/study\/NCT05988216 (2023)."},{"key":"2168_CR562","unstructured":"ClinicalTrials.gov. A study of RJMty19 in refractory systemic lupus erythematosus (SLE), https:\/\/clinicaltrials.gov\/study\/NCT06340490 (2024)."},{"key":"2168_CR563","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and preliminary efficacy of ATA3219 in participants with systemic lupus erythematosus, https:\/\/clinicaltrials.gov\/study\/NCT06429800 (2024)."},{"key":"2168_CR564","unstructured":"ClinicalTrials.gov. Study evaluating SC291 in subjects with severe r\/r B-cell mediated autoimmune diseases (GLEAM), https:\/\/clinicaltrials.gov\/study\/NCT06294236 (2024)."},{"key":"2168_CR565","unstructured":"ClinicalTrials.gov. A phase 1 study of ADI-001 in lupus nephritis. (2024)."},{"key":"2168_CR566","unstructured":"ClinicalTrials.gov. Universal CAR-T cells (BRL-301) in relapse or refractory autoimmune diseases, https:\/\/clinicaltrials.gov\/study\/NCT05859997 (2023)."},{"key":"2168_CR567","unstructured":"ClinicalTrials.gov. An exploratory clinical study of anti-CD19 CAR NK cells in the treatment of systemic lupus erythematosus, https:\/\/clinicaltrials.gov\/study\/NCT06010472 (2023)."},{"key":"2168_CR568","unstructured":"ClinicalTrials.gov. Anti-CD19 CAR-NK cells in refractory\/relapsed systemic lupus erythematosus, https:\/\/clinicaltrials.gov\/study\/NCT06421701 (2024)."},{"key":"2168_CR569","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat. Commun. 15, 2542 (2024).","journal-title":"Nat. Commun."},{"key":"2168_CR570","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1136\/ard.2010.129288","volume":"70","author":"T J\u00f3nsd\u00f3ttir","year":"2011","unstructured":"J\u00f3nsd\u00f3ttir, T., Sundelin, B., Welin Henriksson, E., van Vollenhoven, R. F. & Gunnarsson, I. Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits. Ann. Rheum. Dis. 70, 1172\u20131173 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR571","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/14397595.2015.1060665","volume":"26","author":"Y Tanaka","year":"2016","unstructured":"Tanaka, Y. et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod. Rheumatol. 26, 80\u201386 (2016).","journal-title":"Mod. Rheumatol."},{"key":"2168_CR572","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheum."},{"key":"2168_CR573","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215\u20131226 (2012).","journal-title":"Arthritis Rheum."},{"key":"2168_CR574","unstructured":"ClinicalTrials.gov. AB-101 in combination with B-Cell depleting mAb in patients who failed treatment for class III or IV lupus nephritis or other forms of refractory systemic lupus erythematosus, https:\/\/clinicaltrials.gov\/search?cond=NCT06265220 (2024)."},{"key":"2168_CR575","unstructured":"ClinicalTrials.gov. Open-label single-center study to evaluate the safety and efficacy of combining rituximab and AB-101 in B-cell associated autoimmune diseases. (IRIS-RD-01), https:\/\/clinicaltrials.gov\/study\/NCT06581562?cond=NCT06581562&rank=1 (2024)."},{"key":"2168_CR576","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/0961203320981137","volume":"30","author":"OK Cinar","year":"2021","unstructured":"Cinar, O. K. et al. Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience. Lupus 30, 527\u2013530 (2021).","journal-title":"Lupus"},{"key":"2168_CR577","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler, E. F. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65, 2368\u20132379 (2013).","journal-title":"Arthritis Rheum."},{"key":"2168_CR578","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR579","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/art.42734","volume":"76","author":"BH Rovin","year":"2024","unstructured":"Rovin, B. H. et al. Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis Rheumatol. 76, 247\u2013254 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR580","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00836-6","volume":"8","author":"J Ereno-Orbea","year":"2017","unstructured":"Ereno-Orbea, J. et al. Molecular basis of human CD22 function and therapeutic targeting. Nat. Commun. 8, 764 (2017).","journal-title":"Nat. Commun."},{"key":"2168_CR581","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","volume":"52","author":"DJ Wallace","year":"2013","unstructured":"Wallace, D. J. et al. Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatol. (Oxf.) 52, 1313\u20131322 (2013).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR582","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaut.2019.04.016","volume":"101","author":"R Lorenzetti","year":"2019","unstructured":"Lorenzetti, R. et al. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J. Autoimmun. 101, 145\u2013152 (2019).","journal-title":"J. Autoimmun."},{"key":"2168_CR583","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.38260","volume":"66","author":"R Furie","year":"2014","unstructured":"Furie, R. et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66, 379\u2013389 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR584","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1002\/art.34624","volume":"64","author":"D Wofsy","year":"2012","unstructured":"Wofsy, D., Hillson, J. L. & Diamond, B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 64, 3660\u20133665 (2012).","journal-title":"Arthritis Rheum."},{"key":"2168_CR585","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 3077\u20133087 (2010).","journal-title":"Arthritis Rheum."},{"key":"2168_CR586","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech, J. et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403, 850\u2013859 (2024).","journal-title":"Lancet"},{"key":"2168_CR587","unstructured":"Allen, H. C. & Sharma, P. Histology, plasma cells. StatPearls (2024)."},{"key":"2168_CR588","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149\u20131155 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2168_CR589","doi-asserted-by":"publisher","first-page":"756941","DOI":"10.3389\/fimmu.2021.756941","volume":"12","author":"T Walhelm","year":"2021","unstructured":"Walhelm, T. et al. Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: A nationwide study. Front. Immunol. 12, 756941 (2021).","journal-title":"Front. Immunol."},{"key":"2168_CR590","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615\u20132622 (1999).","journal-title":"Cancer Res."},{"key":"2168_CR591","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander, T. et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474\u20131478 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR592","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00393-008-0427-x","volume":"68","author":"R Voll","year":"2009","unstructured":"Voll, R. & Hiepe, F. Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man. Z. Rheumatol. 68, 150\u2013153 (2009).","journal-title":"Z. Rheumatol."},{"key":"2168_CR593","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","volume":"28","author":"T Ishii","year":"2018","unstructured":"Ishii, T. et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod. Rheumatol. 28, 986\u2013992 (2018).","journal-title":"Mod. Rheumatol."},{"key":"2168_CR594","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41590-022-01340-w","volume":"23","author":"J Tellier","year":"2022","unstructured":"Tellier, J. & Nutt, S. L. The secret to longevity, plasma cell style. Nat. Immunol. 23, 1507\u20131508 (2022).","journal-title":"Nat. Immunol."},{"key":"2168_CR595","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41423-020-00540-4","volume":"18","author":"K Ma","year":"2021","unstructured":"Ma, K. et al. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cell Mol. Immunol. 18, 1739\u20131750 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2168_CR596","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/eji.201847492","volume":"48","author":"T Alexander","year":"2018","unstructured":"Alexander, T. et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur. J. Immunol. 48, 1573\u20131579 (2018).","journal-title":"Eur. J. Immunol."},{"key":"2168_CR597","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","volume":"62","author":"M Mah\u00e9vas","year":"2015","unstructured":"Mah\u00e9vas, M. et al. Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. J. Autoimmun. 62, 22\u201330 (2015).","journal-title":"J. Autoimmun."},{"key":"2168_CR598","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0353-5","volume":"32","author":"H Yun","year":"2015","unstructured":"Yun, H., Zhang, H. L. & Wang, H. Q. Rituximab and bortezomib (RB): A new effective regimen for refractory or relapsed indolent lymphomas. Med Oncol. 32, 353 (2015).","journal-title":"Med Oncol."},{"key":"2168_CR599","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1191\/0961203305lu2239oa","volume":"14","author":"ZG Li","year":"2005","unstructured":"Li, Z. G., Mu, R., Dai, Z. P. & Gao, X. M. T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 14, 884\u2013889 (2005).","journal-title":"Lupus"},{"key":"2168_CR600","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2165\/00063030-200317030-00009","volume":"17","author":"Abetimus.","year":"2003","unstructured":"Abetimus. Abetimus sodium, LJP 394. BioDrugs 17, 212\u2013215 (2003).","journal-title":"BioDrugs"},{"key":"2168_CR601","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1002\/art.23673","volume":"58","author":"MH Cardiel","year":"2008","unstructured":"Cardiel, M. H. et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 58, 2470\u20132480 (2008).","journal-title":"Arthritis Rheum."},{"key":"2168_CR602","doi-asserted-by":"publisher","first-page":"103182","DOI":"10.1016\/j.autrev.2022.103182","volume":"21","author":"J Cajamarca-Bar\u00f3n","year":"2022","unstructured":"Cajamarca-Bar\u00f3n, J. et al. Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmun. Rev. 21, 103182 (2022).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR603","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","volume":"2","author":"MH Park","year":"2018","unstructured":"Park, M. H., Caselman, N., Ulmer, S. & Weitz, I. C. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2, 2090\u20132094 (2018).","journal-title":"Blood Adv."},{"key":"2168_CR604","first-page":"2286","volume":"54","author":"MC Pickering","year":"2015","unstructured":"Pickering, M. C. et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatol. (Oxf.) 54, 2286\u20132288 (2015).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR605","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s10067-017-3823-2","volume":"36","author":"MI de Holanda","year":"2017","unstructured":"de Holanda, M. I., P\u00f4rto, L. C., Wagner, T., Christiani, L. F. & Palma, L. M. P. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin. Rheumatol. 36, 2859\u20132867 (2017).","journal-title":"Clin. Rheumatol."},{"key":"2168_CR606","doi-asserted-by":"publisher","first-page":"1097528","DOI":"10.3389\/fmed.2022.1097528","volume":"9","author":"M Yamaguchi","year":"2022","unstructured":"Yamaguchi, M. et al. Case report: Thrombotic microangiopathy concomitant with macrophage activation syndrome in systemic lupus erythematosus refractory to conventional treatment successfully treated with eculizumab. Front. Med. (Lausanne) 9, 1097528 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"2168_CR607","unstructured":"ClinicalTrials.gov. Study of ravulizumab in proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN) (SANCTUARY), https:\/\/clinicaltrials.gov\/study\/NCT04564339 (2020)."},{"key":"2168_CR608","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee, A. Avacopan: first approval. Drugs 82, 79\u201385 (2022).","journal-title":"Drugs"},{"key":"2168_CR609","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","volume":"8","author":"BP Dixon","year":"2023","unstructured":"Dixon, B. P. et al. Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases. Kidney Int. Rep. 8, 2284\u20132293 (2023).","journal-title":"Kidney Int. Rep."},{"key":"2168_CR610","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1146\/annurev.iy.08.040190.001345","volume":"8","author":"J Van Snick","year":"1990","unstructured":"Van Snick, J. Interleukin-6: an overview. Annu. Rev. Immunol. 8, 253\u2013278 (1990).","journal-title":"Annu. Rev. Immunol."},{"key":"2168_CR611","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol."},{"key":"2168_CR612","doi-asserted-by":"crossref","unstructured":"Chaoyi, M., Shrestha, B., Hui, L., Qiujin, D. & Ping, F. Tocilizumab therapy for persistent high-grade fever in systemic lupus erythematosus: two cases and a literature review. J. Int. Med. Res. 50 (2022).","DOI":"10.1177\/03000605221088558"},{"key":"2168_CR613","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei, G. G. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542\u2013552 (2010).","journal-title":"Arthritis Rheum."},{"key":"2168_CR614","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/art.38091","volume":"65","author":"JC Szepietowski","year":"2013","unstructured":"Szepietowski, J. C. et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 65, 2661\u20132671 (2013).","journal-title":"Arthritis Rheum."},{"key":"2168_CR615","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/art.39722","volume":"68","author":"BH Rovin","year":"2016","unstructured":"Rovin, B. H. et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 68, 2174\u20132183 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"2168_CR616","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3899\/jrheum.210805","volume":"49","author":"RF Van Vollenhoven","year":"2022","unstructured":"Van Vollenhoven, R. F. et al. Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study. J. Rheumatol. 49, 380\u2013387 (2022).","journal-title":"J. Rheumatol."},{"key":"2168_CR617","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","volume":"392","author":"RF Van Vollenhoven","year":"2018","unstructured":"Van Vollenhoven, R. F. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392, 1330\u20131339 (2018).","journal-title":"Lancet"},{"key":"2168_CR618","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/annrheumdis-2018-eular.4143","volume":"77","author":"JL Mart\u00edn-Varillas","year":"2018","unstructured":"Mart\u00edn-Varillas, J. L. et al. FRI0323 Apremilast therapy in refractory skin lupus lesions. Ann. Rheum. Dis. 77, 698\u2013698 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR619","first-page":"1224","volume":"11","author":"A De Souza","year":"2012","unstructured":"De Souza, A., Strober, B. E., Merola, J. F., Oliver, S. & Franks, A. G. Jr. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J. Drugs Dermatol. 11, 1224\u20131226 (2012).","journal-title":"J. Drugs Dermatol."},{"key":"2168_CR620","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","volume":"24","author":"LI Sakkas","year":"2017","unstructured":"Sakkas, L. I., Mavropoulos, A. & Bogdanos, D. P. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives. Curr. Med. Chem. 24, 3054\u20133067 (2017).","journal-title":"Curr. Med. Chem."},{"key":"2168_CR621","doi-asserted-by":"publisher","first-page":"e6031","DOI":"10.1371\/journal.pone.0006031","volume":"4","author":"KJ Scalapino","year":"2009","unstructured":"Scalapino, K. J. & Daikh, D. I. Suppression of glomerulonephritis in NZB\/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells. PLoS One 4, e6031 (2009).","journal-title":"PLoS One"},{"key":"2168_CR622","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10238-016-0427-0","volume":"17","author":"D Wang","year":"2017","unstructured":"Wang, D. et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin. Exp. Med. 17, 333\u2013340 (2017).","journal-title":"Clin. Exp. Med."},{"key":"2168_CR623","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","volume":"10","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. A long-term follow-up study of allogeneic mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem. Cell. Rep. 10, 933\u2013941 (2018).","journal-title":"Stem. Cell. Rep."},{"key":"2168_CR624","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/rheumatology\/keab877","volume":"61","author":"S Goklemez","year":"2022","unstructured":"Goklemez, S. et al. Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. Rheumatol. (Oxf.) 61, 3317\u20133328 (2022).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR625","doi-asserted-by":"publisher","first-page":"100241","DOI":"10.1016\/j.jtauto.2024.100241","volume":"8","author":"M Zare Moghaddam","year":"2024","unstructured":"Zare Moghaddam, M., Mousavi, M. J. & Ghotloo, S. Stem cell-based therapy for systemic lupus erythematous. J. Transl. Autoimmun. 8, 100241 (2024).","journal-title":"J. Transl. Autoimmun."},{"key":"2168_CR626","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","volume":"74","author":"JY Humrich","year":"2015","unstructured":"Humrich, J. Y. et al. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann. Rheum. Dis. 74, 791\u2013792 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR627","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer, C. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 75, 1407\u20131415 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR628","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich, J. Y. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann. Rheum. Dis. 81, 1685\u20131694 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR629","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR630","doi-asserted-by":"publisher","first-page":"e1293","DOI":"10.1002\/cti2.1293","volume":"10","author":"K Liang","year":"2021","unstructured":"Liang, K. et al. Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr\/Tfh ratio in lupus. Clin. Transl. Immunol. 10, e1293 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"2168_CR631","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","volume":"23","author":"M Miao","year":"2021","unstructured":"Miao, M. et al. Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res. Ther. 23, 167 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"2168_CR632","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2","volume":"43","author":"L Llorente","year":"2000","unstructured":"Llorente, L. et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43, 1790\u20131800 (2000).","journal-title":"Arthritis Rheum."},{"issue":"Suppl 2","key":"2168_CR633","doi-asserted-by":"publisher","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel, D. D., Lee, D. M., Kolbinger, F. & Antoni, C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl 2), ii116\u2013ii123 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR634","doi-asserted-by":"publisher","first-page":"e03362021","DOI":"10.1590\/0037-8682-0336-2021","volume":"54","author":"PS Kurizky","year":"2021","unstructured":"Kurizky, P. S. et al. Dramatic secukinumab-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways. Rev. Soc. Bras. Med. Trop. 54, e03362021 (2021).","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"2168_CR635","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1177\/0961203318762598","volume":"27","author":"Y Satoh","year":"2018","unstructured":"Satoh, Y. et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 27, 1202\u20131206 (2018).","journal-title":"Lupus"},{"key":"2168_CR636","first-page":"e17198","volume":"13","author":"R Costa","year":"2021","unstructured":"Costa, R., Antunes, P., Salvador, P., Oliveira, P. & Marinho, A. Secukinumab on Refractory Lupus Nephritis. Cureus 13, e17198 (2021).","journal-title":"Cureus"},{"key":"2168_CR637","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/09612033241242698","volume":"33","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. & Hu, Z. Membranous lupus nephritis secondary to secukinumab therapy: A case report and literature review. Lupus 33, 644\u2013649 (2024).","journal-title":"Lupus"},{"key":"2168_CR638","doi-asserted-by":"crossref","unstructured":"Tu, J. et al. UC-BSCs exosomes regulate Th17\/Treg balance in patients with systemic lupus erythematosus via miR-19b\/KLF13. Cells 11, 4123 (2022).","DOI":"10.3390\/cells11244123"},{"key":"2168_CR639","doi-asserted-by":"publisher","first-page":"e13389","DOI":"10.1111\/dth.13389","volume":"33","author":"JY Liang","year":"2020","unstructured":"Liang, J. Y. et al. Successful treatment of facial localized discoid lupus erythematosus with intralesional betamethasone: A report of three cases. Dermatol. Ther. 33, e13389 (2020).","journal-title":"Dermatol. Ther."},{"key":"2168_CR640","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1161\/CIRCULATIONAHA.107.707661","volume":"117","author":"DM Friedman","year":"2008","unstructured":"Friedman, D. M. et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 117, 485\u2013493 (2008).","journal-title":"Circulation"},{"key":"2168_CR641","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock, D., Keller, F., Rasche, F. M. & H\u00e4ussler, U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44, 61\u201398 (2005).","journal-title":"Clin. Pharmacokinet."},{"key":"2168_CR642","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1093\/rheumatology\/keab347","volume":"60","author":"G Ruiz-Irastorza","year":"2021","unstructured":"Ruiz-Irastorza, G. Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly. Rheumatol. (Oxf.) 60, 5489\u20135490 (2021).","journal-title":"Rheumatol. (Oxf.)"},{"key":"2168_CR643","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/1756-185X.14265","volume":"25","author":"IH Bandhan","year":"2022","unstructured":"Bandhan, I. H., Islam, M. N., Ahmad, H. I. & Ahmedullah, A. K. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int. J. Rheum. Dis. 25, 121\u2013130 (2022).","journal-title":"Int. J. Rheum. Dis."},{"key":"2168_CR644","first-page":"195","volume":"89","author":"EL Dubois","year":"1958","unstructured":"Dubois, E. L. Systemic lupus erythematosus; results of treatment with triamcinolone. Calif. Med. 89, 195\u2013203 (1958).","journal-title":"Calif. Med."},{"key":"2168_CR645","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jama.1958.02990300016004","volume":"167","author":"EL Dubois","year":"1958","unstructured":"Dubois, E. L. Triamcinolone in the treatment of systemic lupus erythematosus. J. Am. Med. Assoc. 167, 1590\u20131599 (1958).","journal-title":"J. Am. Med. Assoc."},{"key":"2168_CR646","first-page":"509","volume":"7","author":"EL Dubois","year":"1958","unstructured":"Dubois, E. L. Evaluation of steroids in systemic lupus erythematosus with particular emphasis on triamcinolone and methylprednisolone. Metabolism 7, 509\u2013525 (1958).","journal-title":"Metabolism"},{"key":"2168_CR647","doi-asserted-by":"publisher","first-page":"109079","DOI":"10.1016\/j.clim.2022.109079","volume":"241","author":"JL Sun","year":"2022","unstructured":"Sun, J. L. et al. Methylprednisolone pulse therapy promotes the differentiation of regulatory T cells by inducing the apoptosis of CD4(\u2009+\u2009) T cells in patients with systemic lupus erythematosus. Clin. Immunol. 241, 109079 (2022).","journal-title":"Clin. Immunol."},{"key":"2168_CR648","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/all.13051","volume":"72","author":"J Banuelos","year":"2017","unstructured":"Banuelos, J., Cao, Y., Shin, S. C. & Lu, N. Z. Immunopathology alters Th17 cell glucocorticoid sensitivity. Allergy 72, 331\u2013341 (2017).","journal-title":"Allergy"},{"key":"2168_CR649","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.immuni.2020.07.002","volume":"53","author":"D Kim","year":"2020","unstructured":"Kim, D. et al. Anti-inflammatory roles of glucocorticoids are mediated by Foxp3(+) regulatory T cells via a miR-342-dependent mechanism. Immunity 53, 581\u2013596.e585 (2020).","journal-title":"Immunity"},{"key":"2168_CR650","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jaci.2004.07.014","volume":"114","author":"C Karagiannidis","year":"2004","unstructured":"Karagiannidis, C. et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J. Allergy Clin. Immunol. 114, 1425\u20131433 (2004).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2168_CR651","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1196\/annals.1321.010","volume":"1024","author":"IJ Elenkov","year":"2004","unstructured":"Elenkov, I. J. Glucocorticoids and the Th1\/Th2 balance. Ann. N. Y. Acad. Sci. 1024, 138\u2013146 (2004).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2168_CR652","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1096\/fj.06-7452com","volume":"21","author":"AC Liberman","year":"2007","unstructured":"Liberman, A. C. et al. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASBE J. 21, 1177\u20131188 (2007).","journal-title":"FASBE J."},{"key":"2168_CR653","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3389\/fimmu.2020.01027","volume":"11","author":"J Shan","year":"2020","unstructured":"Shan, J., Jin, H. & Xu, Y. T cell metabolism: a new perspective on Th17\/Treg cell imbalance in systemic lupus erythematosus. Front. Immunol. 11, 1027 (2020).","journal-title":"Front. Immunol."},{"key":"2168_CR654","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"ZW Lai","year":"2018","unstructured":"Lai, Z. W. et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial. Lancet 391, 1186\u20131196 (2018).","journal-title":"Lancet"},{"key":"2168_CR655","doi-asserted-by":"publisher","first-page":"121766","DOI":"10.1016\/j.biomaterials.2022.121766","volume":"289","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Rapamycin-encapsulated costimulatory ICOS\/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment. Biomaterials 289, 121766 (2022).","journal-title":"Biomaterials"},{"key":"2168_CR656","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.phrs.2014.03.001","volume":"88","author":"C Ulivieri","year":"2014","unstructured":"Ulivieri, C. & Baldari, C. T. Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacol. Res. 88, 41\u201352 (2014).","journal-title":"Pharmacol. Res."},{"key":"2168_CR657","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/annrheumdis-2012-202315","volume":"73","author":"SP Ardoin","year":"2014","unstructured":"Ardoin, S. P. et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann. Rheum. Dis. 73, 557\u2013566 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR658","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/0961203316662719","volume":"26","author":"R Castejon","year":"2017","unstructured":"Castejon, R. et al. Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity. Lupus 26, 355\u2013364 (2017).","journal-title":"Lupus"},{"key":"2168_CR659","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00296-007-0341-6","volume":"27","author":"KH Costenbader","year":"2007","unstructured":"Costenbader, K. H. et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol. Int. 27, 1071\u20131077 (2007).","journal-title":"Rheumatol. Int."},{"key":"2168_CR660","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/ard.2009.109405","volume":"68","author":"MD de Kruif","year":"2009","unstructured":"de Kruif, M. D. et al. Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 68, 1654 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"2168_CR661","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1177\/0961203318772015","volume":"27","author":"PJ Kotyla","year":"2018","unstructured":"Kotyla, P. J. Simvastatin reduces antiphospholipid antibodies formation in patients with systemic lupus erythematosus: a preliminary study. Lupus 27, 1572\u20131573 (2018).","journal-title":"Lupus"},{"key":"2168_CR662","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05132.x","volume":"1183","author":"HA Niederer","year":"2010","unstructured":"Niederer, H. A., Clatworthy, M. R., Willcocks, L. C. & Smith, K. G. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1183, 69\u201388 (2010).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2168_CR663","doi-asserted-by":"publisher","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","volume":"18","author":"AW Zuercher","year":"2019","unstructured":"Zuercher, A. W., Spirig, R., Baz Morelli, A., Rowe, T. & K\u00e4sermann, F. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun. Rev. 18, 102366 (2019).","journal-title":"Autoimmun. Rev."},{"key":"2168_CR664","unstructured":"Sascha Tillmanns, C. K., David P. D\u2019Cruz, Andrea Doria, Eric Hachulla, Reinhard E. Voll, Michael Tansey, Klaus Schollmeier. SM101, a novel recombinant, soluble, human Fc\u03b3IIB receptor, in the treatment of systemic lupus erythematosus: results of a double- blind, placebo- controlled multicenter study [abstract]. Arthritis Rheum. 66, 2833 (2014)."},{"key":"2168_CR665","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10067-012-1978-4","volume":"31","author":"R Topaloglu","year":"2012","unstructured":"Topaloglu, R. et al. C1q deficiency: Identification of a novel missense mutation and treatment with fresh frozen plasma. Clin. Rheumatol. 31, 1123\u20131126 (2012).","journal-title":"Clin. Rheumatol."},{"key":"2168_CR666","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2133.1997.tb14951.x","volume":"136","author":"MJ Hudson-Peacock","year":"1997","unstructured":"Hudson-Peacock, M. J., Joseph, S. A., Cox, J., Munro, C. S. & Simpson, N. B. Systemic lupus erythematosus complicating complement type 2 deficiency: successful treatment with fresh frozen plasma. Br. J. Dermatol. 136, 388\u2013392 (1997).","journal-title":"Br. J. Dermatol."},{"key":"2168_CR667","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1002\/iid3.1041","volume":"11","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy. Immun. Inflamm. Dis. 11, e1041 (2023).","journal-title":"Immun. Inflamm. Dis."},{"key":"2168_CR668","doi-asserted-by":"crossref","unstructured":"Wach, A., Kosa\u0142ka-W\u0119giel, J., Wawrzycka-Adamczyk, K. & Korkosz, M. Therapeutic plasma exchange in catastrophic antiphospholipid syndrome: A rare case with concomitant systemic lupus erythematosus and infection. Pol. Arch. Intern. Med. 134, 16724 (2024).","DOI":"10.20452\/pamw.16724"},{"key":"2168_CR669","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/mrcr\/rxad069","volume":"8","author":"M Kagitani","year":"2024","unstructured":"Kagitani, M. et al. A successful plasma exchange in bridging to rituximab for severe neuropsychiatric lupus and lupus nephritis with viral infections and aspiration pneumonia. Mod. Rheumatol. Case Rep. 8, 276\u2013279 (2024).","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"2168_CR670","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/09612033241230377","volume":"33","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Lu, M., Lin, M. & Gao, Q. Network pharmacology and molecular docking to elucidate the common mechanism of hydroxychloroquine treatment in lupus nephritis and IgA nephropathy. Lupus 33, 347\u2013356 (2024).","journal-title":"Lupus"},{"key":"2168_CR671","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000484955","volume":"44","author":"N An","year":"2017","unstructured":"An, N. et al. Chloroquine autophagic inhibition rebalances Th17\/Treg-mediated immunity and ameliorates systemic lupus erythematosus. Cell Physiol. Biochem. 44, 412\u2013422 (2017).","journal-title":"Cell Physiol. Biochem."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02168-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02168-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:42:04Z","timestamp":1742172124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02168-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":671,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2168"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02168-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}